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1. Introduction 
1.1 Background and justification 
Chronic respiratory disease constitutes a substantial proportion of adult disease globally and in South 
Africa. Underdiagnoses and misdiagnosis of respiratory diseases remains a problem, with many patients 
going without accurate diagnosis and treatment.  There is, in general, a scarcity of data from South Africa 
on local normative values and reference equations for adult lung function and predictors of lung function.  
Accurate and appropriate normal reference values allow for early detection of respiratory illness and 
perform an important role in monitoring respiratory health [13]. 
Respiratory diseases can be classified as either obstructive, restrictive or non-specific ventilator defect 
[15]. Restrictive lung disease implies a reduction in lung size and volume, making it difficult for people to 
fill and expand their lungs with air. Patients with obstructive lung disease either have damage to the lungs 
or suffer from a narrowing of the airways, making exhalation more difficult than normal. Common causes 
of respiratory disease are chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis and 
bronchitis. There is a high prevalence of COPD and asthma in South Africa [2] [3], making these two 
respiratory ailments a significant public health problem.  
1.2 Common Respiratory Diseases in South Africa: Asthma and COPD  
Asthma  
Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyper-
responsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs and 
increased inflammation) when airways are exposed to various risk factors [4] .  
Risk factors for asthma include exposure to allergens (such as those from house dust mites, animals with 
fur, cockroaches, pollens and moulds), occupational irritants, tobacco smoke, respiratory (viral) 
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infections, exercise, strong emotional expressions, chemical irritants, and drugs (such as aspirin and beta 
blockers). Asthma exacerbations are episodic but airway inflammation is chronically present. [5] 
Asthma is diagnosed on the basis of a patient’s symptoms, medical history and lung function. 
Reoccurring wheezing, coughing and difficulty breathing are key symptoms. Additionally the presence of 
atopic diseases such as eczema or hay fever can be suggestive of asthma. Spirometry testing is used to 
measure airflow limitation and reversibility in order to establish a diagnosis of asthma [6].  Diagnostic 
challenges for asthma are common. Patients might not display symptoms at every visit or may only 
display limited symptoms. It can also be difficult to distinguish asthma from COPD and often a trial of 
treatment is needed [3] [4].   
Chronic Obstructive Pulmonary Disease (COPD)  
COPD is a leading cause of death in the world and increases in its prevalence and mortality are predicted 
in the upcoming decades [7] [8]. Tobacco smoking is a major cause of COPD and South Africa has one of 
the highest rates of tobacco smokers in the world [2]. Additional causes of COPD apart from tobacco 
smoking include occupational dust and chemicals, indoor air pollution from biomass cooking and heating 
in poorly ventilated houses. [9]  
GOLD provides a working definition of COPD as “Chronic Obstructive Pulmonary Disease (COPD) is a 
preventable and treatable disease with some significant extra pulmonary effects that may contribute to the 
severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not 
fully reversible. The airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases” [9]. 
Although spirometry results do not fully capture the impact of COPD on a patient’s health, it remains the 
gold standard for diagnosing the disease and monitoring its progression. Spirometry is an essential tool 
for diagnosis and guidelines are tabulated by GOLD for use in classifying COPD [8].  
Typical symptoms of COPD are chronic and progressive dyspnea, cough and sputum production.   
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Although often thought of as a disease of the elderly, recent studies have noted that in certain populations 
there is a high prevalence of COPD in younger adults [8].  
Asthma and COPD 
It is possible for patients to suffer from both asthma and COPD. Individuals with asthma who are exposed 
to noxious agents (such as cigarette smoke) are at risk for developing fixed airflow limitation. Usually it 
is possible to distinguish asthma from COPD, however if an individual has both chronic respiratory 
symptoms and fixed airflow limitation it may be difficult to differentiate between the two diseases [3] [9].   
1.3 Burden of COPD and Asthma in South Africa 
In South Africa, respiratory disease (excluding tuberculosis) was ranked as the seventh most important 
cause of disability adjusted life years in the year 2000 [10]. Asthma is not normally associated with a high 
mortality rate as it is often a well-controlled disease in developed countries. However in South Africa the 
disease is not always well controlled and in the year 2000 it was ranked as the 13th top cause of death 
[11]. The case fatality rate in South Africa is reported as being the 5th highest in the world with 18.5 per 
100,000 asthmatics [12]. In the year 2000, COPD was responsible for 2.3% of all deaths in South Africa 
[11], and a 2007 study by the BOLD collaboration noted the high prevalence of COPD in South Africa 
compared to other countries [16]. 
Due to difficulties with terminology and language barriers, self-reported rates of asthma and COPD often 
under estimate the true prevalence of chronic lung disease. In addition to this, specialised spirometry 
equipment is often only available in specialist facilities. This contributes to the low rates of diagnosis [11] 
and under reporting of the two diseases. 
1.4 Spirometry Diagnostics 
The term “spirometry” refers to common pulmonary function tests which measure the amount (volume) 
and speed (flow) of air that can be inhaled and exhaled. These tests are able to detect whether a patient is 
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suffering from abnormal lung function and respiratory illness. Airflow limitation is best measured by 
spirometry, and this is the most widely available and reproducible test of lung function.  
The graph below displays a volume-time curve which shows the amount of air expired from the lungs as a 
function of time; this is a widely used diagram in the field of spirometry.  
 
Figure A2: Volume Time Curve [12] 
 
The figure above shows some of the common diagnostics provided by spirometry tests. These include 
Forced Vital Capacity (FVC) which is the total volume of air expired after a full inspiration. Forced 
Expiratory Volume in 1 Second (FEV1) which is the volume of air expired in the first second during 
maximal expiratory effort, and the ratio of these two parameters, FEV1/FVC which is the percentage of 
the vital capacity which is expired in the first second of maximal expiration [13]. 
The diagnostic tools provided by spirometry tests allow diagnosis of obstructive, restrictive or mixed 
respiratory abnormality. An improvement in FEV1, FVC or both lung function outcomes after inhaled 
bronchodilator suggests the presence of reversible airflow obstruction. [6]. The results of spirometry tests 
assist in determining which lung disease a patient has, and allows a health care professional to determine 
which treatment should be followed.  
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1.5 The Use of Reference Equations in Pulmonology 
Spirometry tests are a vital component in diagnosing and managing respiratory illness. In order to 
diagnose abnormal lung function, the results of spirometry tests are compared to predicted values, and 
lower and upper limits of normal (LLN and ULN), that are appropriate for the individual being tested [1].  
Although there have been many papers on reference equations for spirometric indices, many of these are 
based on studies with small sample sizes [13]. Spirometry data from African countries is limited and there 
is a strong need for more data in this area. Many reference equations are also developed using a narrow 
age range which limits their relevance in a wider population [13] [1].  
The Global Lung Initiative (GLI) was established in 2012 to address the need for global reference 
equations that are based on a sufficiently large and representative sample, across a wide age range and 
using current methodologies. 
Global Lung Initiative 
Following endorsement by the European Respiratory Society (ERS), the American Thoracic Society 
(ATS), the Asian Pacific Society of Respirology (APSR), the Australian and New Zealand Society of 
Respiratory Science (ANZSRS), the Thoracic Society of Australia and New Zealand (TSANZ) and the 
American College of Chest Physicians (ACCP), the Global Lung Initiative published the 2012 
Spirometric Lung Function regression equations. 
The GLI reference equations differ to normal linear spirometry reference equations as they incorporate a 
spline function which allows for a smooth fit over the entire age range. The reference equations consist of 
three parameters L, M and S which are functions of sex, age, height and ethnicity [1].  
The GLI equations have proven to be a useful contribution to the field and the idea of globally applicable 
reference equations has been welcomed by health care professionals. However studies have indicated that 
the current equations still require work before they can be utilize on a global scale. There was little data 
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included from African studies which is problematic. Research is needed to determine the whether these 
reference equations are appropriate for use in a South African setting.  
1.6 Aim 
To describe lung function in healthy women and identify risk factors associated with abnormal lung 
function.  
Objectives  
1. To describe lung function in a group of healthy adult South African females enrolled in a birth 
cohort study, the Drakenstein Child Health Study (DCHS). 
2. To compare lung function of the group to commonly used reference values, specifically to the 
Global Lung Initiative’s predicted values.   
3. To describe the spectrum of abnormal lung function. 
4. To investigate risk factors for abnormal lung function. 
2. Methods 
2.1 Research design 
This cross-sectional analysis will use data collected by the DCHS.   
The DCHS is a birth cohort study which comprises of 1000 mother-infant pairs. The mothers are enrolled 
at their 2nd antenatal clinic visit and infants are followed up with regular study visits until 5 years of age.  
There is a sub-study within the DCHS which specifically investigates the mothers’ lung function, with 
spirometry results collected for all mothers during the study visit 6 to 10 weeks after birth. Although data 
about infants is also collected as part of the wider DCHS this particular study will focus exclusively on 
data collected from mothers.  
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2.2 Study site, population, and sampling   
The study is located in the Drakenstein area of the Western Cape, South Africa. It is a peri-urban area and 
the study population has a relatively low socioeconomic status. There are two main recruitment areas with 
primary health clinics, Mbekweni has a predominantly Black South African population and TC Newman 
is a predominantly mixed race community. A number of study visits, and the lung function testing, 
happen at Paarl Hospital which is in close proximity to both TC Newman and Mbekweni.  
All mothers attending their 2nd antenatal clinic visit at TC Newman or Mbekweni are invited to join the 
DCHS.  The only screening requirements are that they are over the age of 18, between 20 – 24 weeks 
pregnant and are planning to stay in the area after the birth of their child.  
The sample size for this Maternal Lung Function paper would be determined by the number of mothers 
who have had their 6-10 week visit with lung function testing. There were 462 women in total who had 
data for their lung function test. A post-hoc power calculation was done to determine whether this study 
will be adequately powered to meet its objectives, Appendix A1.   
2.3 Data collection  
The Maternal Medical and Respiratory Enrolment, Maternal Lung Function and Maternal SES case report 
forms (CRFs) were used for this study (Appendix D8).  
Apart from the clinical CRFs listed above, certain lab results will also be included in the analysis. A 
number of specimens are collected; one of them is urine which is requested at the enrolment visit and 
birth visit. Urine specimens were used in a quantitative analysis of urine cotinine (IMMULITE 200 
Nicotine Metabolite, Siemans, Los Angeles, USA) to determine a mother’s smoking status. Smoking 
exposure based on urine cotinine was defined as: active smoker if urine cotinine >500 ng.ml-1; passive 
smoker if urine cotinine 10-500 ng.ml-1 and non-smoker if urine cotinine <10 ng.ml-1 [17].  
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Where a mother’s HIV status is unknown or not recently been tested,  a blood specimen was taken and 
serum used in an ABON™ HIV 1/2/O Tri-Line HIV Rapid Test or  alternatively an ADVANCED 
QUALITY™ Rapid Anti-HIV(1&2) Test HIV test.  Serum from the blood specimens was also used in a 
multiple-allergen Phadiatop® test (UniCAP®-Pharmacia, Sweden) which has shown to be a satisfactory 
method for screening for atopy, with a level greater than > 0.35 ku/l regarded as atopy.   
2.4 Data management 
CRFs are captured into a Microsoft Access database which is structured as a relational database according 
to the Participant identification (PID) number. All data is stored according to the PID number to ensure 
participant confidentiality. There are various checks to minimize data capturing errors and a dedicated 
effort to control the quality of the data.  
Urine cotinine results are used to determine maternal smoking status. These results are made available to 
the Drakenstein study on a lab report form which is also stored in the relational Access database. HIV 
status is collected on the Maternal Medical and Respiratory Enrolment CRF. Atopy results are stored in a 
Microsoft Excel spreadsheet with the PID and results, both are checked thoroughly for quality control 
issues. These results are merged together with the data from the study database.  
The database is stored in a secure network location, which is password protected with user rights. 
Backups are made on a regular basis and no participant names or personal identifiers are stored with the 
data. Data is exported from the database into excel and then into Stata where tables are merged and 
cleaned for statistical analysis. Data collection for the DCHS began in 2013 and is ongoing. Data 
management and manipulation is needed to create a dataset suitable for this study.   
2.5 Data analysis 
The lung function results are only available for a single visit and the analysis will thus be cross-sectional 
in nature.   
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To describe the lung function of the cohort the medians and interquartile ranges of the following 
spirometry results will be presented: FVC and FEV1 and the ratio FEV1/FVC. 
The GLI reference equations will be fitted to the observed data and the model fit assessed by a statistical 
analysis of the model residuals. The GLI predicted values will be compared to the observed values to 
determine abnormal lung function. Reversible lung abnormalities will be defined by a 12% or greater 
increase in FEV1 after bronchodilator. The z scores generated by the GLI reference equations will also be 
considered.  
A multivariate logistic regression model will be fitted to explore risk factors associated with abnormal 
lung function and reversibility. The following clinical covariates of interest will be included in the 
analyses: HIV status, previous / current TB infection, tobacco usage (as measured by urine cotinine), 
medical history, atopy profile and BMI. Socioeconomic information will also be included as a covariate 
of interest. Those covariates with are significant at the 5% and 10% level will be considered in the 
multivariate model.  
Analysis will be done in STATA version 12. 
2.6 Ethical issues 
The ethical principles will be in line with those stated in the Declaration of Helsinki (Fortaleza, Brazil, 
2013) [14] , a declaration developed by the World Medical Association for medical research involving 
human participants.  
The study has been designed taking into account the social and clinical value of the research objectives. It 
is accepted that all research projects carry some element of risk and inconvenience for participants. In 
light of the potential value that this study could generate and given the burden of disease in South Africa, 
and notable lack of data in this field, the potential risks associated with this study are considered 
reasonable. Importantly the study aims to minimize risks to participants and ensure that their well-being 
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takes precedent over all other interests at all times. The welfare of study participants will be closely 
monitored and any participants requiring additional medical attention or counselling will be referred to an 
appropriate health care professional.  
The study is considered to have a high level of scientific validity, it has been designed in line with similar 
international studies and has a team of lung function experts using suitable spirometry equipment and 
following best clinical research practices.   
Participants will have full autonomy to choose what activities within the study they would like to 
participate in, and their decisions will be free from any coercive influence. Before study activity 
commences, participants will be taken through an informed consent process where there will be full 
disclosure about the nature of the study, the risks, benefits and alternatives and an opportunity for 
participants to ask questions. All study materials and CRFs will be translated into mother tongue 
languages of the participants. Participants will also be able to withdraw from the study at any time with 
no penalties.  
There will be equitable selection of participants. All mothers attending an antenatal clinic visit at one of 
the clinics in Paarl are invited to participate in the study, and these mothers come from communities that 
are likely to benefit directly from the findings of the study.  
Participants’ privacy and confidentiality will be well protected. All data will be stored confidentiality and 
using participant identification numbers instead of participant names. Participants files will be kept in a 
locked room and sensitive results and data will be treated and stored carefully.  
3. Time frame 
The DCHS study began enrolling mothers in March 2012 and a large amount of data collection, capturing 
and cleaning has already taken place. As such this time frame focuses on the critical milestones required 
for the data cleaning and analysis of Maternal Lung Function data. 
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Table A1: Timeframe for study schedule for maternal lung function analysis 
 
TIMEFRAME  
 
 J
ul
y 
20
14
 
A
ug
 2
01
4 
S
ep
 2
01
4 
– 
 
  J
an
 2
01
5 
F
eb
 2
01
5 
Departmental and ethical approval     
Data cleaning     
Data analysis     
Writing of manuscript     
Feedback, revisions and changes to manuscript     
Submission of dissertation and dissemination of findings     
4. Dissemination of research findings 
This thesis will be submitted in partial fulfilment of the requirements for a Master of Public Health 
(Epidemiology) degree at the University of Cape Town. The results and findings fall within the 
organisation of the DCHS, findings will be discussed with and presented to the lead investigator Heather 
Zar and study epidemiologist Landon Myer.  
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Appendix A1: Post-hoc power calculation 
The sample size for this Maternal Lung Function paper is determined by the number of mothers who have 
had their 6-10 week visit with lung function testing, there were 462 women in total who had data for their 
lung function test.  
Given that the sample size for this study is fixed, a post-hoc power calculation was done to determine the 
study’s ability to correctly detect a significant effect with respect to mean differences in the spirometry 
results compared to the GLI predicted spirometry values. The observed mean FEV1 value was 2.72 L (sd 
0.44) with a GLI mean predicted value for this cohort of 2.80 L (sd 0.27), this provides a power of 0.91. 
Similarly for FVC with an observed value of 3.15L (sd 0.40) and GLI predicated value of 3.23 L (sd 0.32) 
the statistical power is 0.92. Thus we believe the study is adequately powered to meet its key objectives.  
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1. Introduction and objectives of this literature review 
This literature review provides an overview of the burden of adult respiratory diseases in lower and 
middle income countries (LMICs) and specifically in South Africa. It will review the most common 
respiratory diseases with a specific focus on COPD and Asthma. It will explore measurement and 
diagnostics tools used in the field of pulmonology. Lastly the use of reference equations and the Global 
Lung Initiative are discussed.  
2. Search Strategy 
PubMed and Google Scholar were used to find papers for this literature review. The following search 
terms were used: asthma, chronic obstructive lung disease, respiratory illness, spirometry, lung disease, 
Global Lung Initiative, pulmonology, reference equations, lung cancer, tuberculosis, Human 
Immunodeficiency Virus, low and middle income countries and South Africa. The literature review 
focused specifically on papers that looked at lung disease and included spirometry data or used 
spirometry reference equations.  
The search focused on papers from the African continent but also included those written globally. All 
publications available through to 16 February 2015 were included in this review, and only English 
language articles were included.  
3. The Burden of Adult Lung Disease in Low to Middle Income Countries 
Historically, low and middle income countries (LMICs) have had a high burden of infectious diseases and 
health care budgets and facilities have been focused on responding to these epidemics. In recent years 
more attention has been given to the non-communicable disease (NCD) burdens faced by LMICs, 
including diseases related to respiratory illness.  
Respiratory diseases are classified as either obstructive or restrictive. Patients with obstructive lung 
disease either have damage to the lungs or narrowing of the airways which makes exhalation more 
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difficult than normal.  Obstructive disease is considered to be either reversible (for example asthma) or 
only partially reversible or entirely irreversible (for example chronic obstructive lung disease).  A 
restrictive abnormality is defined by a reduction in total lung capacity with submaximal inspiratory or 
expiratory efforts, or poor peripheral airflow obstruction. Restrictive lung diseases are rarer than 
obstructive respiratory illnesses. Asthma and COPD cause significant burden of disease in LMICs, other 
significant chronic respiratory conditions are tuberculosis (TB),   HIV associated lung disease and lung 
cancer.  
The global burden of asthma has been estimated to be approximately 623 million people of all ages and 
ethnic backgrounds worldwide who suffer from this chronic respiratory illness [15].  The World Health 
Survey (WHS) was developed and implemented by the WHO in 2003. This study surveyed a total of 
178,215 individuals from 70 countries aged 18 to 45 years. Results from this study indicated that the 
global prevalence rates of doctor diagnosed asthma, clinical/treated asthma and wheezing in adults were 
4.3%, 4.5%, and 8.6% respectively [15]. The highest prevalence rates were observed in resource rich 
countries, however the authors note that many resource poor African nations also have a high prevalence 
of the disease but diagnosis rates are low [15]. The burden of asthma is high in urban settings and non-
affluent countries. In these settings, under diagnosis and under treatment remains a problem [16]. There 
are more published research papers on the prevalence and risk factors for asthma in children than in 
adults, and more research is needed in this area, especially in low income settings. Existing research has 
noted that there is an increasing burden of asthma in LMICs and intensified strain on health services to 
provide on-going treatment and care [17]. In 2004 it was estimated that the number of disability-adjusted 
life years (DALYs) lost due to asthma worldwide was approximately 15 million per year [12]. Asthma 
accounted for around 1% of all DALYs lost worldwide which is reflective of the high prevalence and 
severity of asthma [12].  
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COPD is globally associated with high rates of morbidity and mortality [18]. The burden of disease for 
COPD is high and it has previously been ranked twelfth as a worldwide cause of lost quality and quantity 
of life [18]. A study by the World Health Organisation projected that COPD might rank fifth by the year 
2020 as a leading cause of chronic morbidity and mortality [9] .COPD is a leading cause of mortality in 
LMICs  [2] [7]. A systematic review by Finney et al. noted that more population-representative studies 
using appropriate case definitions are needed in Africa to inform prevention and management strategies 
[19]. 
One recent African study, the FRESH AIR study in Uganda, investigated the prevalence and risk factors 
of COPD. The study found the prevalence of COPD in Uganda was highest in people aged 30 – 39 years 
(38% of men and 40% of women), this is unlike in European countries where there are substantially more 
cases in older adults. This reflects the difference in absolute numbers as the populations in Europe are 
older in comparison, in Africa a larger portion of the population are young adults [20]. The study noted 
that in the rural districts in Uganda, COPD starts early in life [8] and there was a notable burden of 
disease in young adults.  
The Burden of Obstructive Lung Disease (BOLD) study investigated COPD prevalence in 12 study sites 
around the world. Prevalence of stage 3 to 4 COPD ranged from 0.8% in Germany to 6.7% in South 
Africa [2]. The study noted that although smoking is still a strong risk factor for the disease, there were 
other notable risk factors such as prior tuberculosis and occupational exposures [2].  
In 2011 it was estimated that there were 8.7 million new cases of TB, TB killed 1.4 million people and 
rates of disease were especially high in parts of Africa [16] . TB disproportionately affects people living 
below the poverty line and is especially prevalent in LMICs [21].  The economic burden of TB care is 
often very high this, and the difficulties with ongoing treatment programmes, causes significant problems 
in many LMICs [21]. Adults who have previously been infected with TB, or who are currently infected 
with TB are likely to have chronic chest symptoms and lung function loss [22]. Ehrlich et al. noted that 
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combined obstructive/restrictive lung function loss was the most common functional outcome for patients 
with pulmonary tuberculosis, with a net obstructive effect on their lung function [22].  
Infection with HIV makes the lungs more susceptible to a wide array of infectious and non-infectious 
diseases. Before widespread antiretroviral therapy (ART) treatment, HIV-infected adults often faced 
serious complications with acute bronchitis, bacterial pneumonia, TB, pneumocystis pneumonia and 
Kaposi’s sarcoma [23].  In recent years, with early ART therapy the incidence of opportunistic and 
recurrent infections has decreased, however there has been a subsequent increase in chronic respiratory 
disease associated with HIV infection [23].  
There is a high burden of respiratory disease amongst HIV infected persons and an association between 
HIV and COPD has been noted in a number of studies [23] [24]. Calligaro and Gray note that there is a 
level of synergism between viral factors, opportunistic infections, conventional influences like tobacco 
smoke and biomass fuel exposure, and possibly, the immunological effects of ART on a patient’s risk of 
developing HIV-associated chronic obstructive lung disease [23]. However they also note that there is a 
scarcity of data exploring these associations and more research is needed in this area.  
The main spirometric abnormality associated with HIV infection in adults is a low FEV1 and / or a low 
FEV1/FVC ratio, which is generally indicative of non-reversible obstructive lung disease [23]. There is a 
strong association between age and the presence of obstructive lung disease, and it is unusual to see a 
high prevalence of obstructive lung disease in young adults. Thus most studies that have shown a higher 
prevalence of obstructive lung disease in HIV infected adults have been based on older cohorts where the 
mean age is often above 40 years of age. [23]   
Lung cancer was one of the most commonly diagnosed cancers worldwide in 2008 with an estimated 1.61 
million cases and 1.38 million deaths [25]. The majority of lung cancer cases (55%) take place in LMIC  
countries, this is an increase compared to previous years where only 31% of lung cancer cases were 
attributed to high income countries [25].   
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4. Common Respiratory Diseases in South Africa 
Chronic respiratory diseases account for a large proportion of NCDs in South African adults. 
Underdiagnoses and misdiagnosis of respiratory diseases remains a problem, with many patients going 
without proper diagnosis and treatment [3].  Asthma and COPD have been reported to be amongst the 
most common respiratory illnesses in adults in South Africa, making these two respiratory ailments a 
significant public health problem [3] and the focus of this section of the literature review.  
4.1 Asthma  
The prevalence of asthma and other atopic diseases has been increasing worldwide in recent years. 
Evidence suggests that the rate of asthma increases as communities become more urbanised and adopt 
western lifestyles [12].  Respiratory disease as a group, excluding TB, was ranked as the seventh most 
important cause of Disability adjusted life years (DALYs) in 2000 in South Africa, with 4.7% of all 
DALYs attributed to respiratory illness [10].  Asthma is largely an adequately controlled disease in 
developed countries and not often a top cause of mortality. In South Africa, asthma ranked as the 13th top 
cause of death (1.5% of all deaths) and 18th as a cause of life years lost (0.9% of all life years) in the year 
2000 [10]. Although South Africa is ranked 25th worldwide in asthma prevalence with an estimated 8.1% 
prevalence over all ages, it is ranked 4th worldwide in the asthma mortality rate in the 5 – 34 year age 
group [12]. Additionally the asthma case fatality rate in South Africa is reported as being the 5th highest in 
the world with 18.5 per 100,000 asthmatics [12].  
It was noted in the South Africa demographic health survey of 2003 that self-reported rates of asthma are 
often an unreliable guide to the true prevalence of asthma [11] . Sometimes there is confusion around the 
terminology used, especially when terms are translated from English to one of the other South African 
National languages. Additionally, spirometric lung function testing is essential for proper diagnosis of 
respiratory illness and is often only available in specialist facilities. Under diagnosis of asthma is also a 
well-documented phenomenon and can add to the low rates of self-reported asthma [11].  
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Asthma is diagnosed on the basis of a patient’s symptoms, signs and lung function testing [4] .  
Spirometry is the preferred method of measuring airflow limitation and reversibility and it is generally 
used to establish a diagnosis of asthma. An increase in FEV1 of more than 12% (or greater than 200L) 
after administration of a bronchodilator is suggestive of reversible airflow limitation, consistent with 
asthma if it is fully reversible. Other studies have also suggested that improvements in both FEV1 and 
FVC should be considered for a diagnosis of reversibility [5]. Because many asthma patients don’t 
demonstrate reversibility at each assessment, repeated testing is advised [6]. Airway reversibility, 
especially partial reversibility is not however specific to asthma and may also be a feature of other 
chronic respiratory diseases such as COPD. 
There are various diagnostic challenges when it comes to diagnosing asthma. Some patients with asthma 
have a chronic cough as their only symptom. Other patients might only suffer from exercise induced 
bronchoconstriction. Distinguishing asthma from COPD can be difficult and may require a trial of 
treatment [4]. Undiagnosed asthma remains a significant problem with many asthmatic patients going 
without proper diagnosis and treatment [26]. Many patients with decreased lung function remain 
undiagnosed because they aren’t symptomatic at the time of their appointment [26]. Additionally patients 
who do present with respiratory problems and who do have reduced lung function are not always 
recognised as being asthmatic [26]. It would also appear that the patient’s perception of dyspnoea and 
their ability to perceive their own dyspnoea plays a vital role in their discussions with their health care 
practitioner and subsequent diagnosis of asthma [26].  
There have been a number of papers which highlight the problematic relationship between smoking and 
asthma, evidence suggests that active smokers, and particularly females, are at a higher risk for 
developing asthma than non-smokers [27] [28].Smoking status and smoking duration are strongly related 
in a “dose-dependent fashion” to the extent of asthma severity. Asthmatic smokers are at risk of 
developing more severe problems, with a higher frequency of exacerbations and a higher number of life 
threatening asthma attacks [27].   
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Lung function is considered to be at its maximum around 20 to 25 years of age. After the age of 25 it 
begins to decline with annual declines in FEV1 of approximately 25-30L per year [28]. However the 
estimated rate of decline is not linear with age and is often greater in elderly patients. Age and the number 
of years for which a patient has been smoking interact to form a strong risk factor for development of 
asthma in adulthood [28].  
The association between obesity and asthma has been observed in a number of studies [29] [30] , there are 
a number of hypotheses for this association; these are mostly based on mechanical, inflammatory and 
common genetic risk factors [29]. There have been few studies specifically investigating the relationship 
between body weight and asthma among reproductive age women.  One study examined the relationship 
between asthma and pre-gravid obesity among reproductive aged women. They found a significant 
association where the odds of asthma were 1.5 fold among women who were overweight or obese [29]. 
Additionally they noted that adult diagnosed asthma was positively associated with a weight change of 
more than 20kgs [29].  
Results from the National Health and Nutrition Examination Survey (NHANES), 2001-2004 [31], found 
that extreme obesity and smoking were strongly associated with current asthma or ever been diagnosed 
with asthma in both women and men [31]. In this study approximately 20% of extremely obese women 
and men had ever been diagnosed with asthma, and within this group of individuals with high BMI, 15% 
reported that they currently had asthma, these rates were much higher than in the normal weight 
population [31].  
Chronic Obstructive Pulmonary Disease (COPD)  
In South Africa, in 2003, COPD was responsible for 2.3% of all deaths, although only 1.1% of years of 
life lost, which can be attributed to the fact that it is primarily a disease of the elderly [10]. Correct 
diagnosis of COPD requires specialised spirometry equipment and this contributes to the current high 
rates of under-diagnoses of the disease in Africa [32]. The BOLD study noted that the study site in South 
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Africa had the highest prevalence of stage two or greater COPD, and that the sites in South Africa, 
Philippines and USA had a much higher than usual burden of clinically significant COPD than other 
countries in the study [2].  
Similarly to asthma, self-reported rates of COPD can be unreliable and can under estimate the true 
prevalence of chronic lung disease. There is often confusion around the terminology used for COPD, for 
example a patient might be told that they have “emphysema” as opposed to “chronic obstructive lung 
disease” or “COPD” [5]. 
Although spirometry results do not fully capture the impact of COPD on a patient’s health, it remains the 
gold standard for diagnosing the disease and monitoring its progression [9]. Spirometry is an essential 
tool for diagnosis and the following specific cut-points are tabulated by GOLD for use in classifying 
COPD. 
Table B1: Spirometric Classification of COPD Severity [9] 
Spirometric Classification of COPD Severity based on Post-Bronchodilator FEV 
Stage 1: Mild FEV1 / FVC < 0.70    
FEV1≥ 80% predicted 
Stage 2: Moderate FEV1 / FVC < 0.70    
50% ≤ FEV1 < 80% predicted 
Stage 3: Severe FEV1 / FVC < 0.70    
30% ≤ FEV1 < 50% predicted 
Stage 4: Very Severe  FEV1 / FVC < 0.70    
FEV1< 30% predicted  
 
Typical symptoms of COPD are chronic and progressive dyspnea, cough and sputum production. For 
many patients, chronic cough and sputum production may precede the development of airflow limitation 
by many years [9].  COPD was previously considered to be a disease of the elderly and not often seen in 
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young adults. Recent studies have noted that COPD can start earlier in life, in the FRESH AIR study in 
Uganda there was a substantial prevalence of COPD in young adults [8].  
Tobacco smoking is a major cause of COPD and one of the most widely recognised risk factors for 
COPD [33] [34]. Many studies have only focused on tobacco smoke when researching COPD, but in 
recent years other risk factors have come to light. Other potential risk factors for COPD include 
occupational dust and chemicals, air pollution (potentially from indoor biomass cooking or heating in 
poorly ventilated houses), airway hyper responsiveness, asthma, and certain genetic variations [5] [33].  
Of relevance to South Africa is the fact that many studies have noted biomass smoke as a primary risk 
factor for COPD in rural areas  [18] [34], exposure to biomass smoke was significantly associated with 
COPD (odds ratio 2.3 95% CI 1.5 – 3.5), acute respiratory tract infection (OR 3.64, 95% CI 2.1 – 6.4) and 
wheeze (OR 2.1, 95% CI 1.5 – 2.9) [35].  
Pulmonary TB has shown to be associated with chronic airflow obstruction, and specifically COPD at the 
time of diagnosis, during treatment and several years after treatment has ended [34] [5] . A nationwide 
South African study suggested that the strongest predictor of COPD was a history of pulmonary TB with 
OR 4.9 (95% CI 2.6 – 9.2) for men and OR 6.6 (95% CI 3.7 – 11.9) for women [5]. In this study, the risk 
of COPD with TB was stronger than the risk from tobacco smoking or exposure to smoke from biomass 
fuel [5].   
COPD was previously considered a disease that affects mainly men, but in recent years there has been a 
rapid increase in the prevalence, morbidity and mortality of COPD in women [18] [36]. It has been 
suggested that the increase in tobacco consumption among women is the reason for the higher rates of 
COPD.   
The table below notes the differences between the onset, etiology and airflow limitation of Asthma and 
COPD.  
 
Emilee Smith MPH Thesis  
 
33 
 
Table B2: Comparison of asthma and COPD 
 
 Asthma  COPD 
Onset Onset normally early in life Onset normally midlife, symptoms 
usually begin at >40 years of age 
Etiology Possible family history of allergies or 
asthma 
Long smoking history or history of 
exposure to environmental pollutants 
Airflow Limitation Reversible Not fully reversible 
5. Spirometry 
Spirometry is the most widely used method for measuring lung function in adults. Spirometry can provide 
critical information about the type and reversibility of lung disease including on the large and small 
airways and the pulmonary parenchyma [37].  It is important to note that the results of a spirometry test 
do not provide an exact diagnosis; rather they provide insight which allows the pulmonologist to compare 
a patient’s lung function to different patterns of abnormalities, this process assists in diagnosing a specific 
lung function disorder.  
Guidelines for performing and interpreting spirometry are published by a number of different 
organisations, including the ERS and the ATS. Good standardization for performing testing is essential 
and tests are very dependent on the effort put in by the patient, thus patient cooperation and awareness is 
vital in obtaining optimal results. Unsuccessful spirometry with suboptimal results may occur in patients 
who have some clinical difficulty (such as chest or abdominal pain) or with patients who do not fully 
understand the directions given to them when performing the test [37]. Patient understanding is especially 
important in health care settings in countries like South Africa. There can be a language barrier between 
the health care professional and the patient, and this can lead to poorly understood instructions and 
ultimately suboptimal test results. Spirometry tests are performed a minimum of three times to ensure that 
the results are reproducible and accurate [37] [6].  
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In order to determine whether a particular patient has impaired lung function ability, the patient’s results 
will be compared to normal or predicted ranges of values that are obtained from large population studies 
of healthy subjects [37] [1] [6] . Measurements are compared to patients with a similar age, height, sex 
and where appropriate ethnicity.  
There are a number of common diagnostics or parameters provided by spirometry tests. These include the 
following:  
FVC -- This is the total volume of air expired after a full inspiration. Patients with obstructive lung 
disease usually have a normal or only slightly decreased vital capacity. Patients with restrictive lung 
disease have a decreased vital capacity.  
FEV1 -- This is the volume of air expired in the first second uring maximal expiratory effort. FEV1 is 
reduced in both obstructive and restrictive lung disease.  
FEV1/FVC -- This is the percentage of the vital capacity which is expired in the first second of maximal 
expiration. In healthy patients FEV1/FVC is usually around 70% or above the lower limit of normal (as 
defined by appropriate reference equations). In patients with obstructive lung disease FEV1/FVC 
decreases and can be as low as 20-30% in severe obstructive airway disease. Restrictive disorders have a 
near normal FEV1/FVC [13].  
Spirometry tests assist in diagnosing ventilatory defects. Patients may suffer from an obstructive, 
restrictive or mixed abnormality. An obstructive ventilatory defect is a reduction of maximal airflow from 
the lung in relation to the maximal volume that can be displaced from the lung. It is suggestive of airway 
narrowing and is defined by a reduced FEV1/VC ratio below the 5th percentile of the predicted value [5]. 
A restrictive ventilatory defect is characterised by a reduction in total lung capacity below the 5th 
percentile of the predicted value, and a normal FEV1 / VC ratio [5]. A mixed ventilatory defect is 
characterised by the coexistence of obstruction and restriction, and is defined physiologically when both 
FEV1/VC and total lung capacity are below the 5th percentiles of their relevant predicted values [5]. 
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6. The Role of Reference Equations in Spirometry 
Spirometry tests play a critical role in diagnosing and managing respiratory illness. Unlike many 
biological indices which often have specific threshold values, pulmonary function typically varies with 
age, standing height, sex and ethnicity. This necessitates that the results of lung function tests are 
compared to predicted values, and lower and upper limits of normal (LLN and ULN), that are appropriate 
for the individual being tested [1] [37].  
There are a large number of published reference equations for adult pulmonary function, mostly for 
spirometric indices. Many of these reference equations are based on studies with small sample sizes, with 
data collected many years ago and with an unrepresentative sample for the greater population [1]. 
Spirometry data for Black Africans is particularly scarce and most of the reference equations are based on 
studies of Caucasian participants. Many prediction equations also were designed for a specific age group, 
which can lead to significant discontinuities as individuals move from one set of equations to another [1]. 
Many health care professionals working in pulmonology use the default settings offered by the spirometry 
equipment’s manufacturer and they are not aware of these shortcomings [55].   
There is, in general, a scarcity of data from South Africa on normative values and reference equations for 
lung function, predictors of low lung function and findings on the impact of HIV on adult lung function 
[3].  Accurate and appropriate normal reference values are needed as they allow for early detection of 
respiratory illness and perform an important role in monitoring respiratory health. 
The GLI was established in 2012 to address the need for global reference equations that are based on a 
sufficiently large and representative sample, across a wide age range and using current methodologies. 
7. The Global Lung Initiative  
The GLI published the 2012 Spirometric Lung Function regression equations based on data collected 
from the following countries: Algeria, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, 
Iceland, India, Iran, Israel, Italy, Mexico, the Netherlands, Norway, Oman, Pakistan, Philippines, Poland, 
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Portugal, South Africa, South Korea, Sweden, Switzerland, Taiwan, Thailand, Tunisia, UK, USA, 
Uruguay and Venezuela. There were various data quality control issues that meant some data was not 
useable, for example, data was discarded if there were missing values for sex, age, height, FEV1 or FVC, 
or where the FEV1/FVC ratio was >1.0 [1]. Additionally, datasets from India, Pakistan, Iran, Oman, the 
Philippines and South Africa were either too small in number for analysis, or could not be combined into 
groups with other sets (due to a high level of heterogeneity) and these were thus excluded from the 
reference equation analysis.  
There were significant differences for spirometric indices between countries, a regression analysis by the 
GLI team highlighted that there was remarkable agreement between some of the datasets but predicted 
values for FEV1 and FVC were significantly lower in other groups. There was no evidence to suggest that 
these differences related to methodological differences or to unrepresentative samples.  
From this the following groups were defined: 
Group Country/region 
‘Caucasian’  Europe, Israel, Australia, USA, Canada, Mexican Americans, Brazil, Chile, Mexico, 
Uruguay, Venezuela, Algeria, Tunisia 
 
‘Black’    African American 
 
‘South East Asian’  Thailand, Taiwan and China (including Hong Kong) south of the Huaihe River and 
Qinling Mountains 
 
‘North East Asian’  Korea and China north of the Huaihe River and Qinling Mountains 
 
The table below displays the differences in the level of pulmonary function between participants in each 
of the groups compared to Caucasians.   
Table B3: Percentage difference in mean pulmonary function by sex and ethnic group compared to 
Caucasians [1] 
 
  Females 
 
FEV1 FVC FEV1/FVC FEF25‐75% 
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African American ‐13.8 ‐14.4 0.6 ‐11.7 
North East Asia ‐0.7 ‐2.1 1.1 ‐7.7 
South East Asia ‐13.0 ‐15.7 2.9 ‐4.3 
  
  Males 
 
FEV1 FVC FEV1/FVC FEF25‐75% 
African American ‐14.7 ‐15.5 0.8 ‐12.9 
North East Asia ‐2.7 ‐3.6 0.9 ‐3.2 
South East Asia ‐9.7 ‐12.3 2.8 ‐0.9 
 
 
Quanjer et al. suggested that the proportional differences in the level of pulmonary function between 
Caucasians, South and North East Asians and African-Americans are compatible with the “out of Africa” 
theory [1]. This theory proposes that mankind originated in Africa and migrated through South East Asia, 
travelling northwards and populating East Asia whilst undergoing evolutionary changes [1], with a 
hypothesis that as people grew taller their lung volumes increased proportionately. There is evidence from 
genetic markers which supports the “out of Africa” theory” [38].  
It is suggested that the ethnic and racial differences in pulmonary function arise from differences in body 
build (specifically the chest size or the ratio of sitting to standing height), socioeconomic status, living in 
an area of high altitude and other potential environmental factors [39] [40] [41]. It is however widely 
accepted that further research is needed into the interaction effect between ethnic group and pulmonary 
function, especially for minority groups [39].  
The GLI reference equations include an “other” group for individuals not represented by the four GLI 
groups, or for individuals of mixed ethnic origins. This “other” group is a composite equation which takes 
the average of the other equations, meaning that individuals in this “other” group are compared to the 
average of the four main ethnic groups. This group is currently in place to facilitate interpretation and 
discussion until a more appropriate solution is developed [39].  
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The GLI equations 
These equations differ slightly from usual spirometric reference equations (which are usually based on 
linear regression models) in that they incorporate spline functions to allow the dependent variable to have 
a smooth and non-linear function.  This is important for a smooth fit over the entire age range rather than 
with previous references equations which led to large jumps between small incremental increases in age.  
The GLI reference equations have three parameters L, M and S which are functions of sex, age, height 
and ethnicity.  
 L measures the skewness 
 S is the coefficient of variation 
 M is the predicted value of FEV1, FVC, FEV1/FVC or other indices  
The general form of the equation is given by: 
Y = a + b*H + c * A + age‐spline + d1 * group + d2* group *A 
 Y = dependent variable 
 H = standing height (cm) 
 A = age (yr) 
 a, b, c, d1 and d2 are coefficients which vary for each ethnic group 
 spline is an age-specific value from the spline function 
 group is a dummy variable, with 0 for Caucasians and 1 otherwise 
Because the reference equations incorporate spline functions the interpretation of the parameters is not as 
simple as with a normal linear regression equation. An example of the workings is given in Appendix B1.  
The current GLI equations are a good start at moving towards globally appropriate prediction equations 
and the idea of globally applicable reference equations has been welcomed by health care professionals. 
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However studies have indicated that the current equations still require work before they can be utilized on 
a global scale. Researchers working with the GLI were not able to gather data for many ethnic minorities 
or any African countries.  There was very little data available from African studies that could be used in 
the reference equation analysis. The reference equations available for Black individuals in the GLI 
equations are based on data from African Americans. Thus, while the GLI reference equations provide 
important insight into lung function analysis, there is an urgent need for reference data and equations that 
are appropriate for African communities. 
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Appendix B1: GLI Reference Equations   
The table below is provided by the GLI Macro and shows the parameters used to calculate L, mu and 
sigma for FEV1.  
 
Table B4: Example parameters for the fields L, mu and sigma used in the GLI reference equations  
 
FEV1 
     
  Male Female 
Age L M S L M S 
log link 0.00000 1.00000 1.00000 0.00000 1.00000 1.00000 
log ht 0.00000 1.00000 0.00000 0.00000 1.00000 0.00000 
coef  int 0.88660 -10.34200 -2.32680 1.15400 -9.69870 -2.37650 
Height  cm 0.00000 2.21960 0.00000 0.00000 2.12110 0.00000 
coef age 0.08500 0.05740 0.07980 0.00000 -0.02700 0.09720 
power age 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
Afr. Am. 0.00000 -0.15890 0.10960 0.00000 -0.14840 0.10160 
NE Asia 0.00000 -0.03510 -0.39730 0.00000 -0.01490 -0.01090 
SE Asia 0.00000 -0.08810 0.03270 0.00000 -0.12080 0.07330 
O/M 0.00000 -0.07080 0.01140 0.00000 -0.07080 0.01140 
 
The GLI reference equations have three parameters L, M and S which are functions of sex, age, height 
and ethnicity.  
 L measures the skewness 
 S is the coefficient of variation 
 M is the predicted value of FEV1, FVC, FEV1/FVC or other indices  
The general form of the equation is given by: 
Y = a + b*H + c * A + age‐spline + d1 * group + d2* group *A 
 Y = dependent variable (may be log transformed) 
 H = standing height (cm) (may be log transformed) 
Emilee Smith MPH Thesis  
 
44 
 
 A = age (yr) (may be log transformed) 
 a, b, c, d1 and d2 are coefficients which vary for each ethnic group 
 spline is an age-specific value from the spline function 
 group is a dummy variable, with 0 for Caucasians and 1 otherwise 
One can see from the table that the coefficients for the predicted values of FEV1 for Females would be: -
0.148 for African Americans, -0.015 for North East Asians , -0.121 for South East Asians and -0.071 for 
participants in the “Other” category.  
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Abstract 
Background: Accurate and appropriate spirometry reference values allow for early detection of 
respiratory illness and perform an important role in monitoring lung health. There is, in general, a scarcity 
of data from Africa, and the Global Lung Initiative (GLI) has published global reference equations but 
models did not include data from African studies.  The aim of this study was to investigate lung function 
in a group of healthy South African females and the applicability of the GLI reference equations.  
Methodology: Maternal lung function testing was undertaken at 6 to 10 weeks post-partum as part of a 
birth cohort study, the Drakenstein Child Health Study. Pre- and post-bronchodilator spirometry was 
performed according to a standardised protocol and correlated with clinical information. Bronchodilator 
response was assessed by repeating spirometry 15 minutes after administration of inhaled 400mcg 
salbutamol.   
Results: A total of 462 women were included, mean age 17 years (range 18 – 42 years). The GLI 
reference equations fitted the observed lung function results well for the group of mothers who did not 
self-report smoking or asthma. There were 64 (14%) mothers with an abnormal Forced Expiratory 
Volume in 1 Second (FEV1) result, 60 (13%) mothers with an abnormal Forced Vital Capacity (FVC), 
and 35 (8%) mothers with an abnormal FEV1/FVC ratio. There were 22 (5%) mothers who had reversible 
FEV1; the rate of undiagnosed reversibility was 4% of the cohort.  High body mass index was associated 
with a higher risk for poor FVC and FEV1/FVC lung function, OR 1.40 (CI: 1.01, 1.65) and OR 1.25 (CI 
1.10, 1.95) respectively. Mothers with a higher socio-economic status had better FEV1 with the adjusted 
SES OR 0.65 (CI 0.36, 1.08).    
Conclusions: There was a high prevalence of abnormal lung function in this cohort of South African 
adult females and a number of cases of undiagnosed reversibility. Spirometry testing is important to 
diagnose lung disease in South African communities. The GLI’s reference equations were appropriate and 
applicable for a cohort of South African adult women.   
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1. Introduction 
Respiratory illnesses constitute a large burden of disease in adults in lower to middle income countries 
including South Africa. Underdiagnoses and misdiagnosis of respiratory diseases remains a problem, 
resulting in suboptimal treatment.  Respiratory disease as a group, excluding tuberculosis, was ranked as 
the seventh most important cause of disability adjusted life years (DALYs) in 2000 in South Africa, with 
4.7% of all DALYs attributed to respiratory illness [10]. Asthma and Chronic Obstructive Pulmonary 
Disease (COPD) are two of the most common respiratory illnesses in adults in South Africa. Although 
South Africa is ranked 25th worldwide in asthma prevalence with an estimated 8.1% prevalence over all 
ages, it is ranked 4th worldwide in the asthma mortality rate in the 5 – 34 year age group [12]. The asthma 
case fatality rate in South Africa is reported as being the 5th highest in the world with 18.5 per 100,000 
asthmatics [12]. In South Africa, in 2003, COPD was responsible for 2.3% of all deaths [10] Studies have 
noted the significantly high prevalence of COPD in South Africa and substantial burden of disease in the 
country compared to other LMICs [2]. 
In African populations the absolute burden of chronic lung disease can include a sizable number of cases 
in younger age groups. For instance, although COPD is normally associated with older patients, the 
FRESH AIR study in Uganda noted that there were a substantial number of cases in young adults and this 
age group contributed the most to the overall burden of disease [8]. African populations often have a 
greater percentage of the population who are young or middle aged adults with few over the age of 65 
years [20]. There is a sizeable potential burden of disease in young African adults and this highlights the 
importance of spirometry tests for diagnosis in this group.  
Several important risk factors for respiratory disease appear common in the South African population. 
Obesity and smoking have been found to be strongly associated with current asthma or ever been 
diagnosed with asthma and a more rapid decline in lung function [31]. Active smokers, and particularly 
females, are at a higher risk for developing asthma than non-smokers [27] [28]. The association between 
obesity and asthma has been observed in a number of studies [29] [30] , there are a number of hypotheses 
Emilee Smith MPH Thesis  
 
49 
 
for this association; these are mostly based on mechanical, inflammatory and common genetic risk factors 
[29].  
Despite the burden of respiratory disease in South Africa, there have been few population-based studies 
employing rigorous measures of lung function. Spirometry tests play a critical role in diagnosing and 
managing respiratory illness. Pulmonary function typically varies with age, standing height, sex and 
ethnicity, and this necessitates that results of spirometry tests are compared to predicted values that are 
appropriate for the individual being tested [1] [37].  Although there are several published reference 
equations for spirometric indices, many of these are based on studies with unrepresentative samples [1]. 
Spirometry data for Black Africans are particularly scarce and most of the reference equations are based 
on studies that had participants of European descent and/or African-American populations. [1]. Accurate 
and appropriate normal reference values that are applicable in a South African setting are urgently 
needed. 
 
The aim of this study was to investigate lung function in an otherwise healthy group of South African 
females. The first objective was to describe lung function; the second was to compare the spirometry 
results of the group to the commonly used reference values provided by the Global Lung Initiative (GLI). 
The third and fourth objectives were to identify women with abnormal lung function and to investigate 
associated risk factors.  
2. Methods  
A cross-sectional analysis of lung function in women enrolled in the Drakenstein Child Health Study 
(DCHS) study was undertaken from March 2012 to June 2014.  
2.1 Study setting and design 
The DCHS is a birth cohort study conducted in a peri-urban, low socio-economic community in South 
Africa. The Maternal Lung Function study is a sub-study within the DCHS, where mothers are invited to 
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have spirometry tests done. DCHS is conducted in the Drakenstein Area in Paarl in the Western Cape, 
South Africa. Women in the study reside in two different neighbourhoods; the first (a predominantly 
mixed race area) is serviced by the TC Newman clinic and the second (a predominantly black African 
area) by the Mbekweni clinic. Inclusion criteria for the study were that women were older than 18 years, 
20 – 24 weeks pregnant; intended to stay in the area for the duration of the study and willing to attend all 
study visits and gave informed consent.  
2.2 Measurements 
Case report forms 
A number of case report forms (CRFs) were used for data collection; these are included in supplementary 
data, Appendix D8.  These CRFs record demographic and anthropometric information as well as 
information about self-reported respiratory related diagnoses, history of diagnoses, and objective 
measures of past illness. A maternal socio-economic CRF provided information used to calculate the 
socio-economic score.   
Clinical specimen measurements 
Apart from the clinical CRFs, mothers were asked for blood and urine specimens. Urine specimens were 
used in a quantitative analysis of urine cotinine (IMMULITE 200 Nicotine Metabolite, Siemans, Los 
Angeles, USA) to determine a mother’s smoking status. Smoking exposure based on urine cotinine was 
defined as: active smoker if urine cotinine >500 ng.ml-1; passive smoker if urine cotinine 10-500 ng.ml-1 
and non-smoker if urine cotinine <10 ng.ml-1[55].  Where a mother’s HIV status was unknown or had not 
recently been tested a blood specimen was taken and serum used in an ABON™ HIV 1/2/O Tri-Line HIV 
rapid test or alternatively an ADVANCED QUALITY™ Rapid Anti-HIV(1&2) HIV test.  Serum from 
the blood specimens was also used in a multiple-allergen Phadiatop® test (UniCAP®-Pharmacia, 
Sweden) which has shown to be a satisfactory method for screening for atopy, with a level greater than > 
0.35 ku/l regarded as atopy.   
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Lung function measurements  
Mothers performed spirometry according to a standardised protocol at 6 – 10 weeks post-partum at a 
study visit at Paarl hospital by trained research staff.  Spirometry data were recorded using a Jaeger 
Masterscope spirometer (CareFusion, Switzerland). The volume signal of the equipment was calibrated 
once daily with a 3-L syringe. Tests were performed with the subject in a sitting position according to 
American Thoracic Society (ATS) / European Respiratory Society (ERS) guidelines [6][56]. The 
following measurements were recorded: Forced expiratory volume in 1 second (FEV1), Forced vital 
capacity (FVC) and the ratio FEV1/FVC.  After oral instruction the subjects exhaled forcefully until three 
acceptable curves were obtained. The best estimates were selected for analysis; these estimates were those 
that were both robust and repeatable. The spirometry was repeated 15min after inhalation of 400 mcg of 
salbutamol given with a metered dose inhaler and spacer to assess response to bronchodilator therapy.  
Quality was assured by ensuring equipment reliability and accuracy (daily calibration of volume 
calibration with a 3L syringe with accurate BTPS correction). All tests were done by 1 of 2 experience 
trained personnel and the first 50 spirometry results were independently reviewed by a pulmonologist to 
ensure quality was consistent. After that, results were reviewed by senior person only when a result was 
abnormal. Reproducibility and repeatability criteria in line with the ATS/ERS recommendations for 
spirometry testing were adhered to. Any test not meeting these criteria was excluded. Reversibility with 
respect to FEV1 was defined as a 12% or greater difference between a mother’s pre-bronchodilator FEV1 
and her post-bronchodilator FEV1 result. Post bronchodilator FEV1 results were compared to the 
predicted values to assess whether reversibility was partial or full.  
2.3 Data analysis 
Data was captured into a DCLHS database in Microsoft Access and analysed using Stata 12.0 (Stata 
Corporation, College Station, USA).  
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Variables were inspected visually by means of histograms and box-plots.  Descriptive statistics were used 
to summarize baseline characteristics. Bivariate associations were calculated using a Pearson’s chi-
squared test (for categorical variables), a Wilcoxon rank sum test (for nonparametric independent 
continuous variables), or a Student’s t-test (for continuous normally distributed variables). Multivariate 
regression tools were used in the GLI prediction equations and standard regression checking methods 
were employed to check model fit, including a review of the residual scatterplots. Logistic regression 
models were fitted to investigate the risk factors associated with abnormal lung function, covariates in 
these models were selected based on their statistical significance with a p-value of less than 0.05.  
Regression results were stratified by study site and the effect sizes were checked to see if there were 
notable differences by site. Site specific regression results are included in Appendix D5. 
A socio-economic (SES) score was calculated from the following inputs: home type, current employment, 
educational achievement, current income and household assets, Appendix D2. The SES index was 
categorised and summarized into a binary variable corresponding to lowest versus highest SES.  
The use of race in epidemiological studies is contentious [39]; often there are more appropriate 
underlying covariates which should be used in casual thinking rather than race. However race is widely 
used to predict spirometry results. To match the methodology used by the Global Lung Initiative, 
participants’ self-reported race is included in this analysis as a potential predictor of lung function.  
2.4 Model Checking of GLI reference equations 
In line with the methodology used by the GLI [1], mothers who self-reported that they smoke or who said 
they had been diagnosed with asthma were dropped from the sample before running the GLI prediction 
equations and checking the model fit, Appendix D4. The mothers making up this group approximate a 
group of healthy adults for which the reference equations would provide a good fit if they are appropriate 
for use in this cohort. A thorough analysis of the predicted values and residuals for the equations indicated 
that the GLI reference equations do provide a good fit for this cohort of women, suggesting that they are 
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appropriate for use in a South African context for both black and mixed race women. Appendix D4 
provides a detailed description of the analysis of the model residuals.   
2.5 Abnormal Lung Function 
Abnormal lung function was defined in three different ways; the first was defined by those participants 
whose observed lung function was outside of the 95% normal limits for them as defined by their GLI 
reference equations. The second was based on participants who displayed lung function reversibility, and 
the third was based on the GOLD Spirometric Classification of COPD Severity using the post-
bronchodilator FEV1 and FEV1 / FVC values. No participants met the requirements in the GOLD 
classification for COPD, thus this model was not explored further.  
3. Results 
During the study period, 462 mothers (n=246 (53%) from TC Newman and n=216 (47%) from 
Mbekweni) were enrolled in the study and performed spirometry.  
3.1 Maternal clinical, demographic and socio-economic characteristics  
The mean age of mothers was 27 years (sd 5.9, age range 18 – 42 years) and mean BMI 26.4 (sd 5.8), 
Table C1.  
Table C1: Anthropometric, demographic and socioeconomic characteristics 
 
 Mbekweni TC Newman Total p-value  
 N = 216 N = 246 N = 462  
 Mean (sd) Mean (sd) Mean (sd)  
Age 27.8 (6.1) 26.3 (5.6) 27.0 (5.9) 0.01 
Height 160.8 (6.8) 158.2 (6.8) 159.4 (6.9) 0.01 
Weight 72.1 (16.5) 63.1 (15.0) 67.3 (16.3) 0.00 
BMI 27.8 (5.9) 25.2 (5.5) 26.4 (5.8) 0.00 
 N(%) N (%) N (%)  
Maternal Socio Economic Status      
      Lowest SES 83 (38) 135 (55) 218 (47) 0.00 
      Highest SES 133 (62) 111 (45) 244 (53) 0.00 
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Ethnicity – Black African 215 (100) 2 (0.8) 217 (47) 0.00 
Previous TB disease  8 (4) 10 (4) 18 (4) 0.84 
Pneumonia Admission last 12 months 0 (0) 1 (0.4) 1 (0.2) 0.42 
Bronchitis Admission last 12 months 0 (0) 1 (0.4) 1 (0.2) 0.42 
Emphysema (self-reported history of 
diagnosis) 
1 (0.4) 0 (0) 1 (0.2) 0.28 
Wheeze (self-reported history of 
diagnosis) 
5 (2) 7 (3) 12 (3) 0.72 
Asthma (self-reported history of 
diagnosis) 
5 (2) 6 (3) 11 (2) 0.93 
Current cough (self-reported)  10 (5) 26 (11) 36 (8) 0.01 
Hay fever (self-reported) 8 (4) 17 (7) 25 (6) 0.13 
HIV positive 68 (33) 7 (3) 75 (17) 0.00 
      CD4 Median  (IQR) 411 (322 – 659) 419 (334 – 577) 411 (322 -630) 0.79 
      Currently taking ARVs 64 (94) 4 (57) 68 (91) 0.08 
Smoking  (Urine Cotinine)     
          Active smoker 30 (15) 119 (50) 149 (32) 0.00 
          Passive smoker 101 (50) 93 (39) 194 (42) 0.05 
Maternal Atopy (Phadiatop)  81 (39) 87 (38) 168 (38) 0.79 
Primagravida 71 (33) 95 (39) 166 (36) 0.18 
Parity Median( IQR) 1 (1-1) 1( 1-1) 1(1-1) -  
SES – Socio Economic Status, TB – tuberculosis, HIV – human immunodeficiency virus, ARV – antiretroviral 
therapy 
 
Mothers from Mbekweni had a higher BMI compared to mothers at TC Newman (BMI 27.8 vs 25.2, 
p<0.001). HIV infection (17%) was substantially higher at Mbekweni (33% positive) compared to 3% at 
TC Newman (p<0.001). Rates of maternal smoking were much higher at TC Newman where 50% of 
moms were classified as active smokers (compared to 15% at Mbekweni, p=0.05) and 39% classified as 
passive smoke exposed (50% at Mbekweni, p<0.001). Many of the women in the cohort are pregnant for 
the first time (36%) with a median parity of 1 previous birth for women in the cohort.  
3.2 Spirometry Results  
The median values before administration of a bronchodilator were FVC (3.11 mL), FEV1 (2.67 mL) and 
FEV1/FVC (87%). After bronchodilator therapy the median values were FVC (3.10 mL), FEV1 (2.78 mL) 
and FEV1/FVC (89 %). There were 22 (5%) mothers who had reversible FEV1, Table C2, of which 7 
mothers had partial reversibility and 15 had complete reversibility (which is suggestive of asthma). 
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Table C2: Bronchodilator Spirometry Results  
 
 
Pre-Bronchodilator 
Median (IQR) 
Post-Bronchodilator 
Median (IQR) 
Difference 
Median (IQR) 
N(%) with 12% or 
greater difference 
FVC (mL) 3.11 (2.84 - 3.42) 3.10 (2.81 - 3.46) 0.00 (-0.05 – 0.07) n/a * 
FEV1 (mL) 2.67 (2.46 - 2.94) 2.78 (2.52 - 3.04) 0.08 (0.02 – 0.14) 22 (5) 
FEV1/FVC 
(%) 
86.38 (82.83 - 89.79) 88.62 (85.57 - 91.05) 2.22 (0.60 – 3.65) n/a * 
* 12% of greater difference is only relevant for FEV1 and thus not calculated for FVC or FEV1/FVC 
Of the 22 (5%) participants with reversible FEV1 abnormality only 3 (14%) self-reported that they 
suffered from asthma. Of the 11 (2.4%) participants who self-reported that they suffered from asthma, 8 
(72%) of them did not show any reversibility in their lung function test. Site differences were checked and 
there was no difference in the rates of reversibility between the two study sites, Appendix D5. There were 
19 (4%) mothers who had an unsuccessful test for FVC, FEV1 or FEV1/FVC. No significant differences or 
trends were noted for those mothers that had an unsuccessful test result; further information about these 
mothers is included in Appendix D3. 
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3.3 The Global Lung Initiative’s Reference Equations 
The GLI reference equations were used to investigate the prevalence of abnormal lung function within 
this cohort of women.  The following table compares the observed values for FVC, FEV1 and FEV1/FVC 
to the lower and upper limits based on the GLI reference equations. The graphs show the observed 
spirometry values and the fitted reference equations lines with a 95% CI around the fitted values. 
Table C3: Spirometry values above and below normal limits as defined by GLI reference equations 
 
  
Values below GLI  Values above GLI  Standardised Z scores 
Lower Limit  
N (%) 
Upper Limit  
N(%) 
Median (IQR) 
FEV1 44 (9.7) 20 (4.4) -0.3 (-0.9 – 0.4) 
FVC 36 (7.9) 24 (5.3) -0.2 (-0.9 – 0.5) 
FEV/FVC 23 (5.1) 12 (2.6) -0.1 (-0.6 – 0.4) 
 
 
 
  
    
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
There were 44 women (10%) who had an observed FEV1 value that was below the Lower Limit of 
Normal (LLN) and 20 (4%) who had a value that was above the Upper Limit of Normal (ULN) for FEV1. 
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There were 36 women (8%) who had an observed value for FVC below the LLN and 24 (5%) who had a 
value above the ULN. The results for FEV1/FVC show that 23 (5%) women had a value below the LLN 
and 12 women (3%) above the ULN. Overall there were 105 (23%) mothers who had abnormal lung 
function.  Overall the standardized z scores had median values of FEV1 -0.3 , FVC -0.2 and FEV1/FVC -
0.1.  
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3.4 Risk Factors associated with respiratory illness  
3.4.1  Risk factors associated with abnormal lung function  
The univariate and multivariate results for risk factors associated with abnormal lung function are shown 
in the table below. 
Table C4: Univariate and multivariate regression results for abnormal lung function  
 
UNIVARIATE ANALYSIS 
  Abnormal FVC Abnormal FEV1 Abnormal FEV/FVC 
  
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Age (years) 1.04 0.99 1.08 0.13 1.05 1.00 1.10 0.03 0.99 0.93 1.05 0.67 
BMI 1.25 1.05 1.23 0.15 1.03 0.98 1.07 0.26 1.10 0.90 1.56 0.05 
Highest SES 0.81 0.47 1.40 0.46 0.66 0.39 1.12 0.12 0.94 0.47 1.88 0.86 
Maternal Atopy 1.03 0.58 1.83 0.91 0.86 0.49 1.50 0.60 1.42 0.71 2.84 0.32 
Smoking - 
Nonsmoker 1.00 - - - 1.00 - - - 1.00 - - - 
Smoking - Passive 0.64 0.31 1.32 0.23 0.43 0.21 0.88 0.02 0.69 0.30 1.62 0.40 
Smoking - Active 0.97 0.48 1.98 0.93 0.95 0.49 1.85 0.88 0.71 0.29 1.74 0.45 
HIV 0.89 0.42 1.90 0.77 1.07 0.53 2.17 0.84 0.83 0.31 2.20 0.70 
Cough (Any) 1.09 0.41 2.92 0.87 3.33 1.20 9.21 0.02 2.58 0.71 9.36 0.15 
TB 1.36 0.38 4.84 0.64 2.40 0.62 9.29 0.21 1.23 0.15 9.87 0.85 
MULTIVARIATE ANALYSIS 
  Abnormal FVC Abnormal FEV1 Abnormal FEV/FVC 
Pseudo R2 
   
2% 
   
5%   
  
3% 
  
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Age 1.04 0.99 1.10 0.08 1.03 0.99 1.09 0.13 1.01 0.95 1.08 0.69 
BMI 1.40 1.01 1.65 0.08 1.01 0.96 1.06 0.80 1.25 1.10 1.95 0.04 
Highest SES n/a* 
  
  0.65 0.36 1.18 0.08  n/a* 
  
  
TB n/a*       3.06 1.07 8.74 0.04  n/a*       
SES – Socio Economic Status, TB – tuberculosis, HIV – human immunodeficiency virus, BMI – body mass index 
 
*only significant covariates included in the multivariate model, SES and TB excluded from multivariate FVC and 
FEV1/FVC model as they were non-significant at the 10% level.  
 
From the results, a high BMI is associated with a higher risk for poor FVC with an odds ratio of 1.40 (CI: 
1.01, 1.65). High BMI is also shown to be associated with an abnormal FEV/FVC result with an OR 1.25 
(CI 1.10, 1.95). 
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SES and TB were only significantly associated with an abnormal FEV1 result. The results show there is 
some evidence to suggest that mothers with a higher SES have better FEV1 results than those mothers 
with a lower SES score, with the adjusted SES OR 0.65 (CI 0.36 ,1.08) . TB has an odds ratio of 3.06 
(1.07; 8.74), those mothers who self-reported that they had previously had TB had a 3.06 higher odds of 
having an abnormal FEV1 result.  
3.4.2  Risk factors associated with reversible obstructive airflow disease 
The univariate and multivariate results for risk factors associated with reversible FEV1 are shown in the 
table below.  
Table C5: Univariate and multivariate regression results for reversible FEV1   
 
    UNIVARIATE ANALYSIS MULTIVARIATE MODEL   
    
Odds 
Ratio 95% CI p-value 
Odds 
Ratio 95% CI p-value 
Pseudo 
R2 
ReversibleFEV1         
    
10% 
  Age (years) 0.99 0.92 1.07 0.87 1.00 0.92 1.09 0.96   
  BMI 0.97 0.90 1.05 0.51 0.98 0.91 1.07 0.70   
  Highest SES* 1.08 0.46 2.54 0.87 
    
  
  Maternal Atopy 3.48 1.38 8.81 0.01 3.42 1.31 8.91 0.01   
  
Smoking – 
Passive* 1.02 0.34 3.08 0.97 
    
  
  Smoking – Active* 0.79 0.23 2.66 0.70 
    
  
  HIV* 1.12 0.37 3.42 0.84 
    
  
  Cough (Any)* 0.55 0.07 4.22 0.57 
    
  
  TB* 2.65 0.57 12.32 0.21 
    
  
  AsthmaAny 8.53 2.09 34.72 0.00 6.63 1.45 30.33 0.02   
* excluded from the multivariate model as covariate was non-significant at the 10% level 
Maternal atopy is strongly associated with reversible FEV1 with an odds ratio of 3.42 (CI 1.29, 9.70), self-
reported asthma is also strongly associated with reversibility in FEV1 with an odds ratio of 6.63 (CI 1.24, 
32.14).  
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5. Discussion 
The results of this study showed that while only a small proportion (5%) of young adult women in this 
setting had reversible FEV1, the vast majority of these (86%) did not self-report a previous diagnosis with 
asthma or another lung disease. Of those with reversible FEV1, most (68%) had completely reversible 
lung function. A small but appreciable proportion of participants had abnormal values for FEV1 FVC 
and/or FEV1/ FVC ratio, but no participants had spirometry results that classified them as having COPD 
according to the GOLD Spirometric Classification. In addition, the GLI reference equations performed 
well at predicting spirometry results for this cohort of women.    
Previous studies have suggested that the global prevalence of doctor diagnosed asthma and 
clinical/treated asthma are both approximately 4-5% [15]. In South Africa the prevalence of asthma has 
been estimated to be approximately 8% across all ages [12]. The BOLD study estimated the prevalence of 
stage I COPD to be 5% of the South African population, stage II was estimated to be 12% and stage III or 
higher was 7% of the population [2].  The FRESH AIR study which also classified participants according 
to spirometry results noted that 6.7% of women in the study aged 30 – 39 years could be classified as 
having COPD and 2% of the entire study population had asthma [8]. Compared to these prevalence rates 
it would seem that the rates of abnormal lung function in the Drakenstein cohort are fairly high.   
Of those mothers who had reversible FEV1, 86% (19/22) of them did not report a previous diagnosis of 
asthma or COPD, suggesting undiagnosed lung disease. This prevalence of undiagnosed reversibility 
corresponds to other studies which have suggested that self-reported rates of lung disease are often an 
unreliable guide to the true prevalence of disease [11]. Given the rates of undiagnosed reversibility it is 
likely that the true prevalence of lung disease in South Africa is likely to be much higher than current 
estimates. Maternal atopy was shown to be strongly associated with reversibility (odds ratio 3.54, CI 1.29, 
9.70) and is well known to be associated with asthma. There was a large percentage of mothers in this 
cohort who were classified as being atopic (n=168, 38%), highlighting the need for more widely available 
spirometry testing in young adults in South Africa. 
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A review of the model fit for the Global Lung Initiatives reference equations showed that the reference 
equations were able to predict lung function remarkably well in this group of young, healthy women. This 
suggests that the GLI reference equations are suitable for use in this cohort of South African adult females 
(although further research is needed to determine the suitability for males). This finding is especially 
useful given the need for spirometry reference equations in South Africa. Another African study, the 
FRESH AIR study, also found the GLI reference equations appropriate for their cohort of adult men and 
women in Uganda [8]. Currently, the Global Lung Initiative does not use data from sub-Saharan Africa in 
its work, but plans to update the sample used for the reference equations to include a larger sample from 
African countries. Preliminary findings suggest that the equations are already very useful in an African 
context and further improvements should lead to an even better model fit for individuals in Africa. This 
will be a notable achievement for public health and will significantly improve lung disease screening, 
diagnosis and treatment rates in African countries.  
This study examines lung health in younger adults and highlights the prevalence of abnormal lung 
function in this group. There have been few studies which explore lung disease in younger adults in sub-
Saharan Africa, as previous literature and recent studies on lung disease in Africa have focused on the 
prevalence of COPD and Asthma in older populations [2] [7] [8]. This study makes an important 
contribution by demonstrating that an appreciable proportion of women of reproductive age in this setting 
are affected by abnormal lung function which is not specifically asthma or COPD.  
Several limitations should be considered when reviewing these findings.  Although there were high rates 
of HIV in this cohort, this study did not show any significant associations between HIV and lung 
function.  It has been suggested that spirometry has limited sensitivity for early HIV-associated lung 
disease; lung diffusion has been proposed as a better lung function measurement tool in this area [23]. 
Further, almost all HIV-infected women in this cohort were on ART and relatively healthy. Participants in 
this study were mothers who were 6-10 weeks post-partum, and research suggests that lung function 
returns to normal within this time post pregnancy [42] , but there are a number of socio-economic and 
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post-pregnancy health related factors that could influence overall health and lung function. Lastly, lung 
function reversibility was defined as a significant improvement in FEV1 after bronchodilator, other 
studies have suggested that one should consider both FEV1 and FVC when defining reversibility [6].  
Given the high prevalence of smoking in this population, it was surprising that the risk factor analysis did 
not show a strong association between smoking and abnormal lung function. It is possible that there were 
too few non-smokers in this cohort to detect a statistically significant result between groups, only 119 
(26%) of mothers were not classified as smokers or passive smoke exposed. Additionally smoking 
duration is relatively short and the effects of it probably not yet seen in this cohort.  
This study had a number of strengths. Well-designed studies collecting spirometry data in African settings 
are scarce. Little is known about adult lung function in peri-urban communities in South Africa, and this 
sample size here of 462 allowed power to detect appreciable associations in this context. The lung 
function tests were done by experienced staff using equipment that was calibrated correctly and the 
collected data was continually checked for quality control errors. The study made use of both self-
reported data and a number of robust clinical measures for weight, height, HIV, smoking and maternal 
atopy. Future research should build on the evidence that suggests the GLI reference equations are 
appropriate for use in this cohort, and test the equations in women, men and children of various ages. 
Additional studies should be conducted to further investigate the prevalence of abnormal lung function in 
South African communities.  
In conclusion, this study makes a useful contribution to the body of knowledge about lung function in 
adult South African females and the use of the GLI reference equations in South Africa. The findings 
confirm the importance of spirometry testing for young adults, and strengthen the evidence that 
undiagnosed asthma and abnormal lung function should be a public health concern in South Africa. 
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Appendix D2: Calculation of SES score 
A Socio-Economic (SES) score was used in the analysis, this score was calculated with the following 
inputs: 
 home type, assigned a value of “1” for house / flat or “0 “for  shack / informal home  
 current employment, assigned a value of “1” for working  or “0” for not working 
 educational achievement,  assigned a value of  “1” for primary education achieved, a “2” for 
some secondary, a “3” for completed secondary, and a “4” for any tertiary 
 income category, assigned a value of “1” for  < R1,000 per month , “2” for  R1,000 - R5,000 / m , 
“3” for > R5,000 pm 
 Household assets, a score of “1” for any of the following: electricity, running water, flush toilet, 
kitchen sink, electric stove, working telephone/ cell phone, a motor car, motorcycle / scooter, 
bicycle. 
A weighted average SES score was calculated which adds up the standardized values of each of the above 
inputs. From this the SES score was categorized into quartiles to form the four groups of lowest SES, 
low-mod SES, mod-high SES and highest SES. 
The SES index was categorised into quartiles to form four groups which were lowest SES, low-mod SES, 
mod-high SES and highest SES. For some of the spirometry outcomes there were very few participants in 
category 3 “mod-high SES” which made model fitting with 4 categories difficult, thus the categories were 
summarized into a binary variable with “0” for lowest SES and low-mod SES and “1” for mod-high SES 
and highest SES.   
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In order to review the psychometric’ properties of this measure the item-item associations were reviewed 
with box plots for categorical measures and a scatter plot for the continuous measure asset sum. This was 
done to review whether the constructed SES score was distributed equally across the selected input 
variables. An assessment of the following graphs indicated that the constructed SES score is indeed 
distributed equally over the independent input factors.  
  
 
 
 
 
 
 
 
Figure D1: Box plot of the SES score by Employment Status  
 
 
 
 
 
 
 
 
 
 
 
Figure D2: Box plot of the SES score by Income Category 
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Figure D3: Box plot of the SES score by Home Type 
 
 
 
 
 
 
 
 
 
Figure D4: Box plot of the SES score by Education  
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Figure D5: Scatter plot of the SES score by Asset Sum 
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Appendix D3: Mothers with unsuccessful lung function test results 
The majority of mothers had successful tests on all of the measures but some had poor results for FVC, 
FEV1 or FEV1/FVC. There were 19 (4%) mothers who had an unsuccessful test for FVC, FEV1 or 
FEV1/FVC.  
The table below shows the number of unsuccessful test results for each spirometry measure. 
Table D1: The number of unsuccessful test results for each spirometry measure 
 FVC 
N(%) 
FEV1 
N(%) 
FEV1/FVC 
N(%) 
Pre-Bronchodilator 0 (0) 2 (0.4) 2 (0.4) 
Post-Bronchodilator 6 (1.3) 11 (2.3) 17 (3.6) 
 
Table D2: Review of mother’s with unsuccessful lung function tests 
 Successful  
Test 
Unsuccessful Test Total p-value 
 N = 443 N = 19 N =462   
 Mean (sd) Mean (sd) Mean (sd)  
Age 27 (6) 27 (6) 27 (6) 0.71 
Height 159 (7) 160 (6) 159 (7) 0.63 
Weight 67 (16) 70 (18) 67 (16) 0.81 
BMI 26 (6) 27 (7) 26 (6) 0.74 
 N(%) N (%) N (%)  
Maternal SES     
  Lowest SES - Low-moderate SES 206 (47) 12 (63) 218 (47) 0.15 
   Mod-High SES - High SES 237 (53) 7 (37) 244 (53) 0.14 
Ethnicity – Black African 209 (47) 8 (42) 217 (47 0.66 
Previous TB infection 18 (4) 0 (0) 18 (4) 0.37 
Pneumonia Admission last 12 
months 
1 (0.2) 0 (0) 1(0.2) 0.89 
Bronchitis Admission last 12 
months 
1 (0.2) 0(0) 1 (0.2) 0.89 
Emphysema (self-reported history 
of diagnosis) 
1 (0.2) 0(0) 1 (0.2) 0.82 
Wheeze (self-reported history of 
diagnosis) 
11 (3) 1 (5) 12 (3) 0.46 
Asthma (self-reported history of 
diagnosis) 
10 (2) 1 (5) 11 (2) 0.40 
Current cough (self-reported) 34 (8) 2 (11) 36 (8) 0.65 
Hay fever (self-reported) 21 (5) 4 (21) 25 (5) 0.002 
HIV positive 73 (17) 2 (11) 75 (17) 0.46 
      CD4 Median  (IQR) 416 (322  - 630)  241 (241 – 241) 411 (322 – 630) 0.18 
      Currently taking ARVs 66 (15) 2 (11) 68 (15) 0.60 
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Smoking  (Urine Cotinine)     
          Active smoker 144 (34) 5 (28) 149 (34) 0.57 
          Passive smoker 185 (44) 9 (50) 194 (44) 0.63 
Maternal Atopy  159 (38) 9 (47) 168 (38) 0.38 
 
No significant differences or trends were noted for those mothers that had an unsuccessful test result. 
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Appendix D4: GLI Model Checking 
In line with the methodology used by the Global Lung Initiative [1], mothers who self-reported that they 
smoke or who said they suffered from asthma were dropped from the sample before running the GLI 
prediction equations and checking the model fit. There were 117 (26%) mothers who self-reported that 
they currently smoke and 11 (2%) who self-reported that they suffered from asthma. After dropping these 
mothers there were 337 adult females left in the sample to check the GLI reference equations model fit.   
The mothers making up this group approximate a group of healthy adults for which the reference 
equations would provide a good fit if they are appropriate for use in this cohort. A thorough analysis of 
the predicted values and residuals for the equations indicate that the GLI reference equations do provide a 
good fit for this cohort of women. The histograms below show the distribution of the model residuals, this 
can be used to review the assumption of normality. All of the residual distributions look approximately 
normal.  
 
 
 
 
 
 
 
Figure D6: Histograms of model residuals for FVC GLI reference equation 
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Figure D7: Histograms of model residuals for FVC GLI reference equation 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D8: Histograms of model residuals for FVC GLI reference equation 
  
Emilee Smith MPH Thesis  
 
76 
 
-2
-1
0
1
2
3
fe
v_
re
si
du
al
2 2.5 3 3.5 4
predfev
Scatter diagram of FEV1 predicted vs residual values
Table 8 below shows the mean observed values for FEV1, FVC and FEV1/FVC, the predicted values, and 
the residuals. The mean values for all residuals are close to zero.  
 Table D3: Observed and Predicted values for GLI reference equations 
 
 
 
 
 
 
The diagrams below show a scatter plot between the predicted values and the model residuals. This 
provides a test of heteroscedasticity. It is a requirement of a linear regression models that there is not 
substantial variation within the variance term. The graphs below show no linear trend or 
heteroscedasticity. A review of these graphs indicates that the variability is approximately equal across all 
values of the independent variable for each model.  
  
 
 
 
 
 
 
Figure D9: Scatter plot of residuals: FEV1 
FEV  mean (sd) 
      FEV observed 2.72 (0.44) 
      FEV Predicted 2.80 (0.27) 
      Residuals -0.07 (0.44) 
FVC  mean (sd) 
      FVC observed 3.15 (0.50) 
      FVC Predicted 3.23 (0.32) 
      Residuals -0.08 (0.47) 
FEV/FVC  mean (sd) 
      FEV/FVC observed 0.86 (0.06) 
      FEV/FVC Predicted 0.87 (0.02) 
      Residuals -0.01 (0.06) 
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Figure D10: Scatter plot of residuals: FVC 
 
 
 
 
 
 
 
 
Figure D11: Scatter plot of residuals: FEV1 /FVC  
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Appendix D5: Site Stratified Spirometry Results and Regression Models 
The tables below show the spirometry data and results of the multivariate regression analysis stratified by 
study site. The stratified analysis was done to determine whether there were any notable differences 
between effects sizes at the two different sites. Measurements and effects were similar across the two 
different sites. 
Table D4: Pre-Bronchodilator FVC, FEV1 and FEV1/FVC results by study site  
Pre-Bronchodilator    
 Mbekweni 
Median (IQR) 
TC Newman  
Median (IQR) 
Total 
Median (IQR) p-value  
FVC (L) 3.15 (2.87 – 3.46) 3.08 (2.81 – 3.40) 3.11 (2.84 – 3.42) 0.23 
FEV1 (L) 2.70 (2.45 – 2.96) 2.65 (2.46 – 2.93) 2.67 (2.46 – 2.94) 0.49 
FEV1/FVC (%) 85.89 (82.63 – 89.03) 87.01 (83.41 – 90.17) 86.38 (82.83 – 89.79) 0.06 
 
Table D5: Post-Bronchodilator FVC, FEV1 and FEV1/FVC results by study site 
Post-Bronchodilator    
 Mbekweni  
Median (IQR) 
TC Newman  
Median (IQR) 
Total 
Median (IQR) p-value 
FVC (L) 3.16 (2.86 – 3.50) 3.08 (2.79 – 3.40) 3.10 (2.81 – 3.46) 0.18 
FEV1 (L) 2.78 (2.54 – 3.06) 2.77 (2.52 – 3.02) 2.78 (2.52 – 3.04) 0.47 
FEV1/FVC (%) 87.80 (85.34 – 90.56) 88.28 ( 85.91 – 91.87) 88.62 (85.57 – 91.05) 0.07 
 
Table D6: Levels of reversibility in FEV1 results by study site   
Reversible FEV1    
 Mbekweni  
N (%) 
TC Newman  
N (%) 
Total  
N (%) p-value 
No reversibility  206 (95) 234 (95) 440 (95) 1.00 
Reversibility  10 (5) 12 (5) 22 (5) 1.00 
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Table D7: Multivariate regression results stratified by study site 
 
Abnormal FVC 
  Mbekweni TC Newman 
Pseudo R2 
   
2% 
   
2% 
  
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Age 1.04 0.97 1.12 0.28 1.05 0.99 1.12 0.13 
BMI 1.03 0.95 1.11 0.50 0.94 0.88 1.02 0.13 
Abnormal FEV 
  Mbekweni TC Newman 
Pseudo R2 
   
  
   
  
  
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Age 1.00 0.93 1.08 0.91 1.07 1.01 1.14 0.03 
BMI 1.05 0.97 1.13 0.23 0.99 0.93 1.06 0.84 
High SES 0.80 0.33 1.94 0.62 0.64 0.31 1.34 0.24 
TB 2.64 0.47 14.89 0.27 3.85 0.98 15.14 0.05 
Abnormal FEV/FVC 
  Mbekweni TC Newman 
Pseudo R2 
   
2% 
   
2% 
  
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Age 1.02 0.93 1.12 0.67 1.00 0.92 1.10 0.93 
BMI 1.02 0.83 1.03 0.15 0.92 0.83 1.03 0.15 
ReversibleFEV1 
  Mbekweni TC Newman 
Pseudo R2 
   
21% 
   
9% 
  
Odds 
Ratio 95% CI 
p-
value 
Odds 
Ratio 95% CI 
p-
value 
Age (years) 0.94 0.82 1.08 0.40 1.04 0.93 1.16 0.52 
BMI 0.97 0.85 1.12 0.71 1.02 0.92 1.14 0.72 
Maternal Atopy 11.08 1.50 81.62 0.02 2.55 0.75 8.68 0.14 
AsthmaAny 3.24 0.23 45.42 0.38 14.64 1.98 108.49 0.01 
 
  
Emilee Smith MPH Thesis  
 
80 
 
Appendix D6: Journal Guidelines for Authors, Respiratory Research 
Instructions for authors 
Research Articles 
Presubmission enquiries | Submission process | Preparing main manuscript text | Preparing illustrations and figures | Preparing 
tables | Preparing additional files | Style and language  
See 'About this journal' for descriptions of different article types and information about policies and the refereeing process. 
Presubmission enquiries 
If you wish to make a presubmission enquiry about the suitability of your manuscript, please email the editors who will respond 
to your enquiry as soon as possible. 
Submission process 
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. 
The submitting author takes responsibility for the article during submission and peer review.  
Please note that Respiratory Research levies an article-processing charge on all accepted Research Articles; if the submitting 
author's institution is a BioMed Central member the cost of the article-processing charge may be covered by the membership (see 
About page for detail). Please note that the membership is only automatically recognised on submission if the submitting author 
is based at the member institution.  
To facilitate rapid publication and to minimize administrative costs, Respiratory Research prefers online submission.  
Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time; when users return to the 
site, they can carry on where they left off. 
See below for examples of word processor and graphics file formats that can be accepted for the main manuscript document by 
the online submission system. Additional files of any type, such as movies, animations, or original data files, can also be 
submitted as part of the manuscript.  
During submission you will be asked to provide a cover letter. Use this to explain why your manuscript should be published in 
the journal, to elaborate on any issues relating to our editorial policies in the 'About Respiratory Research' page, and to declare 
any potential competing interests. You will be also asked to provide the contact details (including email addresses) of potential 
peer reviewers for your manuscript. These should be experts in their field, who will be able to provide an objective assessment of 
the manuscript. Any suggested peer reviewers should not have published with any of the authors of the manuscript within the 
past five years, should not be current collaborators, and should not be members of the same research institution. Suggested 
reviewers will be considered alongside potential reviewers recommended by the Editor-in-Chief and/or Editorial Board members.  
Assistance with the process of manuscript preparation and submission is available from BioMed Central customer support team. 
We also provide a collection of links to useful tools and resources for scientific authors on our Useful Tools page. 
File formats 
The following word processor file formats are acceptable for the main manuscript document:  
 Microsoft word (DOC, DOCX) 
 Rich text format (RTF) 
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 Portable document format (PDF) 
 TeX/LaTeX (use BioMed Central's TeX template) 
 DeVice Independent format (DVI) 
TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile if you use TeX format. During the TeX 
submission process, please submit your TeX file as the main manuscript file and your bib/bbl file as a dependent file. Please also 
convert your TeX file into a PDF and submit this PDF as an additional file with the name 'Reference PDF'. This PDF will be used 
by internal staff as a reference point to check the layout of the article as the author intended. Please also note that all figures must 
be coded at the end of the TeX file and not inline. 
If you have used another template for your manuscript, or if you do not wish to use BibTeX, then please submit your manuscript 
as a DVI file. We do not recommend converting to RTF. 
For all TeX submissions, all relevant editable source must be submitted during the submission process. Failing to submit these 
source files will cause unnecessary delays in the publication procedures. 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Research Articles 
Manuscripts for Research Articles submitted to Respiratory Research should be divided into the following sections (in this 
order): 
 Title page 
 Abstract 
 Keywords 
 Background  
 Methods  
 Results and discussion 
 Conclusions 
 List of abbreviations used (if any) 
 Competing interests 
 Authors' contributions 
 Authors' information  
 Acknowledgements 
 Endnotes 
 References 
 Illustrations and figures (if any) 
 Tables and captions 
 Preparing additional files 
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should 
be provided, in square brackets and include the corresponding database name; for example, [EMBL:AB026295, 
EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. 
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of 
Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-
Prot Protein Database (Swiss-Prot). 
You can download a template (Mac and Windows compatible; Microsoft Word 98/2000) for your article. 
For reporting standards please see the information in the About section.  
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Title page 
The title page should: 
 provide the title of the article 
 list the full names, institutional addresses and email addresses for all authors 
 indicate the corresponding author 
Please note: 
 the title should include the study design, for example "A versus B in the treatment of C: a randomized controlled trial X 
is a risk factor for Y: a case control study" 
 abbreviations within the title should be avoided 
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured into separate sections: Background, the 
context and purpose of the study; Methods, how the study was performed and statistical tests used; Results, the main findings; 
Conclusions, brief summary and potential implications. Please minimize the use of abbreviations and do not cite references in 
the abstract. Trial registration, if your research reports the results of a controlled health care intervention, please list your trial 
registry, along with the unique identifying number (e.g. Trial registration: Current Controlled Trials ISRCTN73824458). Please 
note that there should be no space between the letters and numbers of your trial registration number. We recommend manuscripts 
that report randomized controlled trials follow the CONSORT extension for abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background  
The Background section should be written in a way that is accessible to researchers without specialist knowledge in that area and 
must clearly state - and, if helpful, illustrate - the background to the research and its aims. Reports of clinical research should, 
where appropriate, include a summary of a search of the literature to indicate why this study was necessary and what it aimed to 
contribute to the field. The section should end with a brief statement of what is being reported in the article. 
Methods  
The methods section should include the design of the study, the setting, the type of participants or materials involved, a clear 
description of all interventions and comparisons, and the type of analysis used, including a power calculation if appropriate. 
Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in 
parentheses in the Methods section. 
For studies involving human participants a statement detailing ethical approval and consent should be included in the methods 
section. For further details of the journal's editorial policies and ethical guidelines see 'About this journal'. 
For further details of the journal's data-release policy, see the policy section in 'About this journal'. 
Results and discussion 
The Results and discussion may be combined into a single section or presented separately. Results of statistical analysis should 
include, where appropriate, relative and absolute risks or risk reductions, and confidence intervals. The Results and discussion 
sections may also be broken into subsections with short, informative headings. 
Conclusions 
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This should state clearly the main conclusions of the research and give a clear explanation of their importance and relevance. 
Summary illustrations may be included. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of abbreviations can be provided, 
which should precede the competing interests and authors' contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal 
or financial relationship with other people or organizations. Authors must disclose any financial competing interests; they should 
also reveal any non-financial competing interests that may cause them embarrassment were they to become public after the 
publication of the manuscript. 
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at 
the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they 
have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
 In the past three years have you received reimbursements, fees, funding, or salary from an organization that may in any 
way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization 
financing this manuscript (including the article-processing charge)? If so, please specify. 
 Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication 
of this manuscript, either now or in the future? If so, please specify. 
 Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received 
reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the 
content of the manuscript? If so, please specify. 
 Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests  
Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or 
any other) to declare in relation to this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript should be 
specified in this section. 
According to ICMJE guidelines, An 'author' is generally considered to be someone who has made substantive intellectual 
contributions to a published study. To qualify as an author one should 1) have made substantial contributions to conception and 
design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising 
it critically for important intellectual content; 3) have given final approval of the version to be published; and 4) agree to be 
accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. Acquisition of funding, collection of data, or general supervision of the 
research group, alone, does not justify authorship.  
We suggest the following kind of format (please use initials to refer to each author's contribution): AB carried out the molecular 
genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT 
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International review of cytology. London: Academic; 1980. p. 251-306. 
OnlineFirst chapter in a series (without a volume designation but with a DOI) 
Saito Y, Hyuga H. Rate equation approaches to amplification of enantiomeric excess and chiral symmetry breaking. Top Curr 
Chem. 2007. doi:10.1007/128_2006_108. 
Complete book, authored 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: Blackwell 
Science; 1998. 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. 
http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999. 
Online database 
Healthwise Knowledgebase. US Pharmacopeia, Rockville. 1998. http://www.healthwise.org. Accessed 21 Sept 1998. 
Supplementary material/private homepage 
Doe J. Title of supplementary material. 2000. http://www.privatehomepage.com. Accessed 22 Feb 2000. 
University site 
Doe, J: Title of preprint. http://www.uni-heidelberg.de/mydata.html (1999). Accessed 25 Dec 1999. 
FTP site 
Doe, J: Trivial HTTP, RFC2169. ftp://ftp.isi.edu/in-notes/rfc2169.txt (1999). Accessed 12 Nov 1999. 
Organization site 
ISSN International Centre: The ISSN register. http://www.issn.org (2006). Accessed 20 Feb 2007. 
Preparing illustrations and figures 
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Illustrations should be provided as separate files, not embedded in the text file. Each figure should include a single illustration 
and should fit on a single page in portrait format. If a figure consists of separate parts, it is important that a single composite 
illustration file be submitted which contains all parts of the figure. There is no charge for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising the quality of your figures. 
Formats 
The following file formats can be accepted: 
 PDF (preferred format for diagrams) 
 DOCX/DOC (single page only) 
 PPTX/PPT (single slide only) 
 EPS 
 PNG (preferred format for photos or images) 
 TIFF 
 JPEG 
 BMP 
Figure legends 
The legends should be included in the main manuscript text file at the end of the document, rather than being a part of the figure 
file. For each figure, the following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. 
Figure 1, 2, 3 etc); short title of figure (maximum 15 words); detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce 
figures or tables that have previously been published elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of publication, will be used to create a cover page for the PDF 
version of your article. The cover page will also display the journal logo, article title and citation details. The image may either be 
a figure from your manuscript or another relevant image. You must have permission from the copyright to reproduce the image. 
Images that do not meet our requirements will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and screen dumps), JPEG, BMP, DOC, PPT, 
CDX, TGF (ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a 
title (above the table) that summarizes the whole table; it should be no longer than 15 words. Detailed legends may then follow, 
but they should be concise. Tables should always be cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in A4 portrait or 
landscape format. These will be typeset and displayed in the final published form of the article. Such tables should be formatted 
using the 'Table object' in a word processing program to ensure that columns of data are kept aligned when the file is sent 
electronically for review; this will not always be the case if columns are generated by simply using tabs to separate text. Columns 
and rows of data should be made visibly distinct by ensuring that the borders of each cell display as black lines. Commas should 
not be used to indicate numerical values. Color and shading may not be used; parts of the table can be highlighted using symbols 
or bold text, the meaning of which should be explained in a table legend. Tables should not be embedded as figures or 
spreadsheet files. 
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Larger datasets or tables too wide for a landscape page can be uploaded separately as additional files. Additional files will not be 
displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma separated values (.csv). As 
with all files, please use the standard file extensions. 
Preparing additional files 
Although Respiratory Research does not restrict the length and quantity of data included in an article, we encourage authors to 
provide datasets, tables, movies, or other information as additional files. 
Please note: All Additional files will be published along with the article. Do not include files such as patient consent forms, 
certificates of language editing, or revised versions of the main manuscript document with tracked changes. Such files should be 
sent by email to respiratory-research@biomedcentral.com, quoting the Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and should be included as additional files. Since many 
weblinks and URLs rapidly become broken, Respiratory Research requires that supporting data are included as additional files, 
or deposited in a recognized repository. Please do not link to data on a personal/departmental website. The maximum file size for 
additional files is 20 MB each, and files will be virus-scanned on submission.  
Additional files can be in any format, and will be downloadable from the final published article as supplied by the author. We 
recommend CSV rather than PDF for tabular data. 
Certain supported files formats are recognized and can be displayed to the user in the browser. These include most movie formats 
(for users with the Quicktime plugin), mini-websites prepared according to our guidelines, chemical structure files (MOL, PDB), 
geographic data files (KML).  
If additional material is provided, please list the following information in a separate section of the manuscript text: 
 File name (e.g. Additional file 1) 
 File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and a URL of an 
appropriate viewer if format is unusual) 
 Title of data 
 Description of data 
Additional files should be named "Additional file 1" and so on and should be referenced explicitly by file name within the body 
of the article, e.g. 'An additional movie file shows this in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely available 
tools. The following are examples of suitable formats. 
 Additional documentation  
o PDF (Adode Acrobat) 
 Animations  
o SWF (Shockwave Flash) 
 Movies  
o MP4 (MPEG 4) 
o MOV (Quicktime) 
 Tabular data  
o XLS, XLSX (Excel Spreadsheet) 
o CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
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Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way that they will be browsable from within the full 
text HTML version of the article. In order to do this, please follow these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in the root. 
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or 
"http://yourdomain.net/images/picture.jpg" or "C:\Documents and Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 characters. 
4. Access the index.html file and browse around the mini-website, to ensure that the most commonly used browsers 
(Internet Explorer and Firefox) are able to view all parts of the mini-website without problems, it is ideal to check this 
on a different machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is in the root of the ZIP, and 
that the file has .zip extension, then submit as an additional file with your article. 
Style and language 
General 
Currently, Respiratory Research can only accept manuscripts written in English. Spelling should be US English or British 
English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise.  
Respiratory Research will not edit submitted manuscripts for style or language; reviewers may advise rejection of a manuscript if 
it is compromised by grammatical errors. Authors are advised to write clearly and simply, and to have their article checked by 
colleagues before submission. In-house copyediting will be minimal. Non-native speakers of English may choose to make use of 
a copyediting service. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please visit our page on Writing titles and abstracts 
for scientific articles.  
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. American Scientist also provides a 
list of resources for science writing. For more detailed guidance on preparing a manuscript and writing in English, please visit the 
BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when first used and a list of abbreviations can be 
provided following the main manuscript text. 
Typography 
 Please use double line spacing. 
 Type the text unjustified, without hyphenating words at line breaks. 
 Use hard returns only to end headings and paragraphs, not to rearrange lines. 
 Capitalize only the first word, and proper nouns, in the title. 
 All pages should be numbered. 
 Use the Respiratory Research reference format. 
 Footnotes are not allowed, but endnotes are permitted. 
 Please do not format the text in multiple columns. 
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 Greek and other special characters may be included. If you are unable to reproduce a particular special character, please 
type out the name of the symbol in full. Please ensure that all special characters used are embedded in the text, 
otherwise they will be lost during conversion to PDF. 
Units 
SI units should be used throughout (liter and molar are permitted, however). 
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Appendix D7 : Informed Consent Form 
DRAKENSTEIN CHILD LUNG HEALTH STUDY  
CONSENT AND INFORMATION SHEET FOR MOTHERS – MAIN COHORT 
April 2014 
 
CONSENT FORM AT ENROLMENT 
You and your child are invited to take part in a study that is being done in the Drakenstein sub-district, in 
collaboration with the Universities of Cape Town and Stellenbosch. The following information describes the study 
and you and your child’s role. Please read this carefully and feel free to ask any questions. 
 
Why is this study being done? 
Lung infections and chest problems are common in young children. This study is being done to find out the effect of 
chest infections in the first year of life on the development of lung disease in children.  The study will also look at a 
number of other factors that may affect your child’s health.  
 
You and your child will be enrolled in the study at the time of his/ her birth. After that, you and your child will be 
carefully followed up for a few years. You and your baby will be followed regularly at your primary health care 
clinic and at Paarl Hospital. During these visits, we will assess the health of you and your child by using 
questionnaires and doing tests. Should your baby get sick with a chest infection, then he/ she will be carefully 
investigated to try and find out the cause of this infection. This study will help us to better understand why children 
get chest illness and may help to improve child health. 
 
What must I do if I agree to take part in the study? 
If you agree to participate in this study, we will follow you and your child regularly to assess his/ her health. In the 
first year, we will see you and your child at Paarl hospital at delivery/birth of your child, 6-10 weeks, 1 year and 2 
years. We will also follow you and your child at your regular primary health care clinic visits for routine 
immunizations at 6, 10, 14 weeks, 6 and 9 months. Your child may also be seen every 2 weeks to closely monitor 
his / her health and to investigate which germs are present in your child’s nose. We will ask you some questions 
about your child’s health, nutrition, growth and development, and any chest illnesses. We will do regular tests to 
watch these. These tests are described in more detail below.  
 
We will also ask you and your child to visit Paarl Hospital once a year for a study visit. At this visit, you will be 
asked some questions about you and your child’s health. Your child will be examined. Tests will be done on you and 
your child to assess whether there is any chest problem. The tests that may be done on your child are: 
Blood tests - these will be to test for allergies or blood problems. 
A test of the mucus from the nose (nasopharyngeal swab) to test for infection. 
Saliva will be collected to check for germs which may cause pneumonia  
A skin test for tuberculosis infection. 
A urine test for smoke exposure. 
A stool test to check what germs are in the stool. 
A set of developmental measures in a subset of infants. 
At 7-10 weeks of age a breathing test will be done while your baby is sleeping, to measure the air moving in and out 
of his/her lungs.  
Your child may be asked to undergo a safe, painless brain scan at 2-4 weeks of age    
A skin test if your child has a rash           
  
 
The tests YOU will be asked to complete are: 
A blood test to test to check for any other factors that may predispose your child to certain lung illnesses and 
storage. 
A blowing test to check how healthy your lungs are  
If you are breast feeding, a small sample of breast milk to test the nutrition in the milk your child is receiving. 
A sample of mucus from your nose to check for germs in your nose 
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Questionnaires about your socioeconomic status and your levels of emotional distress, stress, life events, and drug 
and alcohol use.  If a mental health condition or abuse is suspected, you will be referred to the appropriate local 
services.  You may also be invited to return to undergo more thorough follow-up.  This voluntary follow-up session 
will involve a clinical/psychiatric interview; and a neuropsychological assessment that tests your memory, problem-
solving skills, and your attention. You will also be given a questionnaire to complete about your experiences while 
in the Drakenstein study.  
A 5-minute videotaped session of you and your child playing together.  This will used to study how different 
mothers and their babies play with each other 
A urine test for drug and alcohol use 
A swab from your vagina which will be taken when you give  birth 
A stool specimen while you are at the hospital for your child’s birth. 
Swabs from your skin and from your cheek at the time when you give birth. 
 
We will only share your test results with primary health care staff if it indicates that you or your child require 
treatment or further follow up.   For some assessments, study staff may follow up with you and provide you with 
information on where you can seek help, if necessary. 
 
Should your child get sick with a chest infection, then additional tests will be done to try and find out the cause of 
your child’s illness. The tests that will be done will depend on how sick your child is and what the illness is. These 
tests may include: 
Blood tests to test for infections, at the time of the illness, and again 4-6 weeks afterwards  
A test of the mucus from the nose (nasopharyngeal swab) to test for infection 
A skin test for tuberculosis infection. 
A test of the mucus from the lungs (induced sputum test) for chest infections  
A urine test for smoke exposure 
Chest X-ray. 
Breathing test 
A ultrasound test of the lungs 
 
If your child is enrolled in the study and is admitted to hospital, he/she will be followed up in hospital by a member 
of the study team. The study member will ask you questions about your child’s illness, and some tests may be done, 
including a nose swab and an induced sputum. All of these tests are usual for investigating the cause of pneumonia.  
 
Blood that is drawn from the umbilical cord during birth and at the study visits will be stored for possible further 
studies including genetic studies (to investigate whether there are particular genes that may predispose a child to 
pneumonia or other illnesses).   
 
A member of the study team will pay you a visit at your home before you give birth and in the 6 months after your 
baby is born to collect more information about you and your baby’s living conditions. 
 
What are the benefits of my child being in the study? 
You and your child will be closely followed for the first few years of your child’s life. Any medical illness or 
problem should be found soon after it develops. Your child’s growth and development will be carefully followed. If 
an illness or problem is found then your child will be promptly investigated and treated. If your child gets sick you 
will be able to take him/ her to your usual health facility, where additional tests to find out the cause of your child’s 
illness may be done, depending on how sick your child is. If your child requires hospitalisation, then he/ she will be 
hospitalised at Paarl hospital as is usually done. If your child is hospitalised, then one of the study staff will see your 
child in hospital and additional investigations may be done to try and find out the cause of the illness. Therefore the 
study offers an opportunity for your child to receive appropriate medical care.  The study will also help us to better 
understand the causes of illness in children, and identify the things that may harm their health. We hope that this will 
lead to improvements in child health.  
 
What are the risks to my child? 
There are no major risks to your child. There may be some discomfort associated with some of the tests we will do. 
These tests are listed below: 
(1) Blood tests 
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Your child may feel sore when blood samples are taken with a needle. Where possible an anaesthetic cream will be 
used to dull the pain from the needle. Some bruising may occur, but this is not harmful and will disappear. Only a 
small amount of blood (not more than 3 teaspoons) will be taken from your child at any time. 
(2) Nasopharyngeal swab 
A sample of mucus will be taken from your child’s nose, to test for germs that can cause chest infections and to 
monitor which germs are usually in your child’s nose. Your child may experience minor discomfort when the nasal 
swab is done. Occasionally it can cause bleeding from the nose, but this is not serious, and usually stops by itself. 
(3) TB skin test 
A small injection is made on your child’s arm. This is to test whether your child has TB or not, and will be done at 
regular visits.  Your child will experience minor discomfort due to the needle, with the skin test. There may also be 
irritation of the skin if the test is positive (reactive). This test will need to be checked 2-3 days after the injection is 
given. 
(4) Induced sputum 
Your child will be given salt-water through a nebulizer to loosen the mucous in the lungs. Then a sample of that 
mucus will be suctioned, or your child will be asked to cough up the mucus.  Your child may experience a little 
discomfort while the sputum test is done. He/ she may develop some coughing or have a small amount of bleeding 
from the nose after this. These are not serious. Occasionally this test can cause the airways of the lungs to close. If 
this occurs your child will be given medicine through an inhaler/nebulizer to open the airways. 
(5) Breathing test 
This test is done after a child recovers from pneumonia, and at the 6-10 week, 1 year and 2 years follow up visits at 
Paarl Hospital, while your child is asleep and should not cause any discomfort. While your child is asleep a mask 
will be put on his/ her face and the air going in and out of his/ her lungs while breathing will be recorded.   
(6) Stool test 
This test may be done monthly on your child and then every 6 months after 1 year.   Study staff will collect stool 
from your child’s nappy if passed during a study visit.  If there is no stool available, a small tube will be inserted 
into your child’s bottom and some stool will be sucked out with a syringe. The tube is thin and bendable and is only 
put in 1-2 centimeters to reach stool. There is a very small chance of bleeding at the rectum right where the tube 
goes is.  
(7) Ultrasound test of the lungs 
This test will be done if your child develops pneumonia so as to better see how the infection is affecting your childs 
lungs.  This is a very safe procedure and there are no side effects. 
 
What are the risks to you? 
There are no major risks to you. You may feel some discomfort with some of the following tests: 
Blood tests 
You will experience discomfort when blood samples are taken with a needle. Some bruising may occur, but this is 
not harmful and will disappear. 
(2) Lung function test 
This test will be done at each visit to Paarl Hospital. You will be asked to blow into a machine that tests how healthy 
your lungs are. You will then be given an inhaler with medicine that opens up the chest, and asked to blow into the 
machine again. You should not experience any discomfort during this procedure. You may feel shaky after the 
medicine, and your heartbeat may be faster, but this will only last for a short while. 
 
Will I be paid to participate in the study? 
No, you will not be paid to participate in this study.  If you agree to take part, we will reimburse your transport costs 
for visits that are not part of your routine antenatal or well baby clinic visits. 
 
Will there be any cost to participate in the study? 
No, there will be no cost to you. 
 
How long will my child be in the study? 
This consent form is for permission for you and your child to participate in the study for the first year. However, 
your child will be involved in the study for at least 2 years, with the regular routine clinic visits, as well as hospital 
visits at 6-10 weeks, 1 year and 2 years.   Each year we will ask you again to sign permission for you and your child 
to continue in the study for another year. You may withdraw from the study at any time. All personal information 
that you provide, will remain confidential. 
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Will my child’s participation in the study be confidential? 
All information that you provide will be considered confidential, and no mention of you or your child’s name will 
appear on the stored samples or in any publication in connection with this study. No persons other than the health 
care workers overseeing your child’s care and the study nurses and doctors will have access to any information that 
identifies your child personally.  All your test results will not be disclosed to anyone other than for the purpose of 
treating you if there is a problem. 
 
Does my child have to be in the study? 
You can choose not to take part in the study. This will not affect the quality of care your child receives. We will ask 
you to sign a new consent form each year when you visit Paarl hospital. Each year we will explain what we propose 
to investigate for that year. You will be able to decline to participate at any time should any part of the study be 
unacceptable to you, you may still take part in the rest of the study. 
 
What do I do if I have any questions? 
If you have any questions about this study, you can ask study staff, the Principal Investigator or the lung study 
doctor at: 021 860 2802.  For questions about your rights as a study participant call the Human Research Ethics 
Committee, Faculty of Health Sciences, University of Cape Town, Tel: 021-4066492 
 
 
Informed Consent 
I, _____________________________ understand the information contained in this consent form, as explained to me 
in a language that I understand and I am prepared to participate in this study, with my child. 
 
I agree to allow study staff to access my medical and hospital records as well as those of my child during the course 
of the study.  
 
Storage of samples 
If any of the samples I have provided for this research project are unused or leftover when the project is completed: 
 
�  I consent to my samples being stored for future research of any type which has been approved by a Human 
Research Ethics Committee including for genetic testing 
or �  I do not consent to my samples being stored for future research 
 
Storage of your child’s samples 
If any of the samples my child has provided for this research project are unused or leftover when the project is 
completed: 
 
�  I consent to my child’s samples being stored for future research of any type which has been approved by a 
Human Research Ethics Committee including for genetic testing 
or �  I do not consent to my child’s samples being stored for future research 
 
2. To be completed by mother: 
 
Mother’s Name:______________________________________________________________ 
Mother’s Signature: ___________________________________________________________ 
Date: ______________________________________________________________________ 
 
3. Study staff providing information:  Study staff confirming consent: 
Name: ___________________________ _ Name: ____________________________ 
Role in Study:_______________________ Role in Study:_______________________ 
Signature: __________________________ Signature: __________________________ 
Date: ______________________________ Date: ______________________________ 
 
4. If the mother is unable to read or write the entire counselling process must be observed by an independent witness 
who can then confirm the procedure once the mother has given consent. 
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Fingerprint of mother: 
 
Witness: 
I confirm that I am independent of the study and that I witnessed the entire enrolment counselling process in the 
home language of the mother. 
Name:________________________________________________________________ 
Signature: _____________________________________________________________ 
Date: ________________________________________________________________ 
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Appendix D8: Case Report Forms 
 
CRF: Maternal Lung Function Testing 
 
 
 
 
 
Study Details 
 
1 Time arrived (24 hour clock)  
2 Length                                            cm 
3 Weight                                           kg 
4 Room temperature                                                                0C 
5 Pressure                                          hPa 
6 Position □ Sitting 
□ Standing 
7 Additional information:  
 
 
Equipment Calibration – Jaeger Peumotachograph 
 
Time Action Recording value File Reference 
8  Verify Syringe Vol 9           L 10           L  
 
Spirometry 
 
 Test Time 
11.1-13.1 
FVC 
11.2-14.2 
FEV1 
11.3-14.3 
FEV1/FVC 
11.4-14.4 
MMEF 
11.5-14.5 
Comments 
11 
Test 1 
      
 
12 
Test 2 
      
 
13 
Test 3 
      
14 
Best 
      
 
15  
Total number of attempts:  _________________ 
 
 
  
                                   Mother Participant ID:  _ _ _ _ / _ /_ /_ _          Date:  _ _ / _ _ _ / _ _ _ _ 
              Child Participant ID: _ _ _ _ / _ /_ /_ _           
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Quality 
 
Comment 
Effort 1
6 
□ Maximal 
□ Submaximal 
1
7 
 
Acceptable* 
*meets SOP criteria: start and 
end of test, free from artefact 
1
8 
□ Yes 
□ No 
1
9 
 
Repeatable 
<150ml difference best two FVC 
and FEV1 
2
0 
□ Yes 
□ No 
2
1 
 
 
 
 
Bronchodilator 
 
22 Time given  
(24 hour clock) 
 
23 Dose of bronchodilator                                                                             mcg 
Spirometry 
 
Test Time 
24.1-26.1 
FVC 
24.2-27.2 
FEV1 
24.3-27.3 
FEV1/FVC 
24.4-27.4 
MMEF 
24.5-27.5 
Comments 
 
24 Test 1       
 
25 Test 2       
 
26 Test 3       
27 Best       
 
28  
Total number of attempts: _______________________________ 
 
 
 
Quality 
 
Comment 
Effort 2
9 
□ Maximal 
□ Submaximal 
3
0 
 
Acceptable* 
*meets SOP criteria: start and 
end of test, free from artefact 
3
1 
□ Yes 
□ No 
3
2 
 
Repeatable 
<150ml difference best two FVC 
and FEV1 
3
3 
□ Yes 
□ No 
3
4 
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 CRF: Maternal Respiratory & Medical Enrolment Form  
 
 
 
 
PREGNANCY & CURRENT CONDITION 
 1 When was your last menstrual period?  _ _ / _ _ _/ _ _ _ _  
DD / MMM / YYYY 
 2 When is your expected date of delivery?  
_ _ / _ _ _/ _ _ _ _  
DD / MMM / YYYY 
3 Are you currently well? �Yes  
�No  
 
4 Has a doctor or nurse told you that you have any of the following 
health problem/s during this pregnancy?   
Tick all that apply.  
 
�Asthma 
�TB 
�Emphysema 
�Chronic Bronchitis 
�Pneumonia 
�Cold/Flu 
�Excessive vomiting 
�Diabetes 
�High blood 
pressure/eclampsia/pre-eclampsia 
�Pelvic inflammatory disease 
�Heart problem 
�Depression 
�HIV 
�Urine Infection 
�Other  
(specify): ____________________ 
 
5 Are you currently taking medication or was medication prescribed 
today?  
  If yes, record in medication chart. 
�Yes 
�No 
 
 6 At the time you became pregnant, were you using any family 
planning?  
�Yes 
�No 
 
 7 At the time you became pregnant, were you trying to have a baby? �Yes 
�No 
 
   Please fill in the following information for mother’s previous pregnancies: 
  (Data abstraction from ANC card).  For “sex” record F or M.  For “status” A=alive,  
 NND = Neonatal death; ID = Infant death; IUD = Intra-uterine death. 
 (A)  Year (B)  Gestation (C)    Delivery (D)  Weight (E) Sex (F) Status 
8  FT / Prem NVD / CS  M / F A / NND / ID / 
IUD 
9  FT / Prem NVD / CS  M / F A / NND / ID / 
IUD 
10  FT / Prem NVD / CS  M / F A / NND / ID / 
IUD 
11  FT / Prem NVD / CS  M / F A / NND / ID / 
IUD 
                                   Mother Participant ID:  _ _ _ _ / _ /_ /_ _          Date:  _ _ / _ _ _ / _ _ _ _ 
              Child Participant ID: _ _ _ _ / _ /_ /_ _           
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12  FT / Prem NVD / CS  M / F A / NND / ID / 
IUD 
13  FT / Prem NVD / CS  M / F A / NND / ID / 
IUD 
 
 
Abbreviated version.   
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CRF: Socioeconomic Status 
 
 
 
 
Socioeconomic Status 
1 How many children (under 18 
years) do you have? 
 
Number: ___________________ 
2 How many people normally live 
in your household? (Include 
people who live there for more 
than 6 months of the year) 
 
 
Number: ___________________ 
3 How many of these are adults 
over 18 years?  
 
 No Adults 
 1-3 Adults 
 More than 3 adults  
(Please specify: ___________) 
4 How many of these adults over 
18 years are women and how 
many are men? 
If none over 18, please indicate “0” 
 
4.1 
 
Number of men: _______________ 
 
4.2 
  
  Number of women: _____________ 
5 How many of these are children 
aged 5 to 18 years? 
If none, please write “0” 
 
Number: ________________ 
 
6 How many of these children aged 
5 to 18 years are girls and how 
many are boys? 
If none between 5 and 18, please 
indicate “0” 
 
6.1 
 
Number of girl(s): 
 
6.2 
 
Number of boy(s): 
7 How many of these are children 
younger than 5 years?  
If none, please write “0” 
 
Number:___________  
8 How many of these children 
younger than 5 years are girls and 
how many are boys? 
If none younger than 5, please 
indicate “0” 
 
8.1 
 
Number of girl(s): 
 
8.2 
 
Number of boy(s): 
9 What is your relationship to each 
adult or child living with you at 
home?  
Please tick all that apply. 
 
 Your spouse/partner  
 Your son or daughter 
 Your son-in-law or daughter-in-law                                              
 Your grandchild    
 Your parent 
 Your parent-in-law                                              
 Your brother or sister                                                                                                                                                                      
 Your nephew or niece                                                                                                                                                    
 Your adopted/foster/step-child                                                                                                                                
                                   Mother Participant ID:  _ _ _ _ / _ /_ /_ _          Date:  _ _ / _ _ _ / _ _ _ _ 
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 Other  
(specify): _______________________ 
                                                                                                                                                                    
 Not related                                                                                                                                                 
 
 
 
10 
 
What is your Race?  
 
 Black  
 White 
 Coloured 
 Indian/asian 
 Other  
(specify):__________________________________ 
 
11 What language do you speak at 
home?  
 English 
 Afrikaans 
 isiXhosa 
 Other  
(specify): ____________________________ 
12 What is your religion?   Muslim 
 Christian 
 Jewish 
 None 
 Other 
 (specify): ________________________________ 
13 Where were you born?  
 
13.1 13.2 
 In Paarl                 
 Outside of Paarl, in the 
Western Cape                                                                                                                       
 
 Outside of the Western 
Cape, in South Africa (eg. 
Eastern Cape, Kwazulu 
Natal etc.)                                                                  
Please specify: 
_______________________                                                                                                                 
 Outside of South Africa                                                                                                                                              Please specify:
________________________ 
14 How far did you get in school?  
 
 No education           
 Completed Grade 1 (Sub A) to Grade 5 (Standard 3)           
 Completed Grade 6 (Standard 4) to Grade 7 (Standard 5)               
 Completed Grade 8 (Standard 6) to Grade 11 (Standard 
9), ie. High school without matriculating     
 Completed Grade 12 (Standard 10) ie. High school with 
matriculating  
 Part of university/college/post-matric education    
 Completed university/college/post-matric education  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
15 What is your current employment 
situation?  
 
 Working Now                         
 Self-employed                                           
 Looking for work: Unemployed                                                                                                                                        
 Temporarily Laid Off                                                                                                                                                                                                                                                                             
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Abbreviated version. 
 Homemaker                                                                                                                                                                 
 Student                                                                                                                                                                           
 Illness/sickness                                                                                                                                                                      
 Disabled                                                                                                                                                                            
 Other  
(please specify): ___________________ 
 
